Implant for heart valve

Information

  • Patent Grant
  • 11517436
  • Patent Number
    11,517,436
  • Date Filed
    Friday, May 29, 2020
    3 years ago
  • Date Issued
    Tuesday, December 6, 2022
    a year ago
Abstract
An implant includes a clip and a clip-controller interface. The clip is disposed laterally from a central longitudinal axis of the implant, includes first and second arms articulatably coupled to each other, and sandwiches a leaflet of a heart valve between the first and second arms by articulation between the first and second arms, such that the second arm is disposed laterally from the first arm. The clip-controller interface is reversibly coupled to a clip controller of a delivery tool, and includes first and second portions. The first portion is linearly slidable by the clip controller. The second portion is articulatably coupled to the first portion and to the second arm, such that linear sliding of the first portion causes the second portion to (i) articulate with respect to the first portion, and (ii) push the second arm to articulate toward the axis. Other embodiments are also described.
Description

This application is related to PCT application IL2012/000292 to Gross et al., entitled, “Techniques for percutaneous mitral valve replacement and sealing,” filed Aug. 5, 2012, which published as WO 2013/021374.


FIELD OF THE INVENTION

Some applications of the present invention relate in general to valve replacement. More specifically, some applications of the present invention relate to prosthetic valves for replacement of a cardiac valve.


BACKGROUND

Ischemic heart disease causes regurgitation of a heart valve by the combination of ischemic dysfunction of the papillary muscles, and the dilatation of the ventricle that is present in ischemic heart disease, with the subsequent displacement of the papillary muscles and the dilatation of the valve annulus.


Dilation of the annulus of the valve prevents the valve leaflets from fully coapting when the valve is closed. Regurgitation of blood from the ventricle into the atrium results in increased total stroke volume and decreased cardiac output, and ultimate weakening of the ventricle secondary to a volume overload and a pressure overload of the atrium.


SUMMARY OF THE INVENTION

For some applications of the invention, a prosthetic valve support is provided for facilitating minimally invasive (e.g., transcatheter and/or transluminal) implantation of a prosthetic valve at a native valve of a subject. The native valve typically has native check valve functionality, i.e., it functions as a check valve. It is understood that a diseased valve has sub-optimal native check valve functionality, however the term “check valve functionality,” as used in the context of the specification and in the claims, when used with respect to a native valve, refers to the native level of check valve functionality of the native valve. The prosthetic valve support is typically couplable to the native valve (e.g., to leaflets thereof) of the subject without eliminating the check valve functionality of the native valve. The prosthetic valve is subsequently implanted at the native valve by coupling the prosthetic valve to the prosthetic valve support, typically by expanding the prosthetic valve within one or more openings defined by the prosthetic valve support. The implantation of the prosthetic valve at the native valve replaces, at least in part, the check valve functionality of the native valve with substitute check valve functionality of the prosthetic valve. The prosthetic valve support comprises tissue-engaging elements, such as clips. Typically, but not necessarily, the prosthetic valve support further comprises (1) an upstream support portion, configured to be placed against an upstream surface of the native valve, and shaped to define one of the openings, and (2) a stabilizing element, shaped to define another of the openings.


For some applications, the prosthetic valve support is configured to be coupled to the native valve (e.g., to leaflets thereof) without eliminating the check valve functionality of the native valve, by allowing (1) the native leaflets to define a single orifice, and (2) the native valve to function as a single check valve (e.g., to function in a manner that is generally similar to the natural (e.g., physiological) function of the native valve). For some applications, the prosthetic valve support is configured to be coupled to the native valve (e.g., to leaflets thereof) without eliminating the check valve functionality by coupling together respective portions of two leaflets, such that (1) the native leaflets define two orifices, and (2) the native valve functions as two (e.g., parallel) check valves.


For some applications, it is hypothesized that the use of a two-component implant (i.e., comprising the prosthetic valve support and a separate prosthetic valve), advantageously facilitates delivery of the prosthetic valve via a catheter narrower than 28 Fr (e.g., by allowing the use of a ‘minimalistic’ prosthetic valve, such as a prosthetic valve with few or no appendages).


For some applications, it is hypothesized that the use of a prosthetic valve support that does not eliminate check valve functionality of the native valve, facilitates the separate delivery of the prosthetic valve support and the prosthetic valve (i.e., a two-stage delivery), and thereby further facilitates the use of a narrow catheter.


For some applications, it is further hypothesized that the use of the prosthetic valve support enhances the check valve functionality of the native valve, and thereby provides both (1) “repair” of the native valve, and (2) an implantation site that is pre-prepared for subsequent implantation of a prosthetic valve at a later date, should such implantation be subsequently considered necessary.


There is therefore provided, in accordance with an application of the present invention, apparatus for use with a prosthetic valve for implantation at a native valve of a subject, the native valve including at least one native leaflet, the apparatus including:


a prosthetic valve support, including:

    • an upstream support portion, being configured to be placed against an upstream side of the native valve, and having an inner perimeter that defines an opening that is configured to receive the prosthetic valve, and
    • at least one clip:
      • including at least two clip arms and a clip-controller interface, the clip-controller interface being coupled to at least one of the clip arms, and
      • being configured to be coupled to a native leaflet of the native valve; and


at least one clip controller, reversibly couplable to the clip-controller interface, and configured to facilitate opening and closing of the clip.


In an application, the at least two clip arms include a first clip arm, configured to be disposed against an upstream surface of the leaflet, and a second clip arm, configured to be disposed against a downstream surface of the leaflet.


In an application, the clip controller is configured to facilitate opening and closing of the clip irrespective of a state of expansion of the prosthetic valve support.


In an application, the at least one clip includes at least a first clip and a second clip, and the second clip is openable and closeable independently of the first clip.


In an application, the at least one clip includes at least a first clip and a second clip, and the first clip is fixedly coupled to the second clip, and is configured to be decoupled from the second clip.


In an application, the at least one clip is configured to be coupled to a single native leaflet of the native valve.


In an application, the at least one clip is configured to be lockable such that the first clip arm is locked with respect to the second clip arm.


In an application:


the native valve includes at least a first native leaflet and a second native leaflet,


the at least one clip includes at least a first clip and a second clip, the first clip being configured to be coupled to the first leaflet, and the second clip being configured to be coupled to the second leaflet, and


the prosthetic valve support is configured such that, when (1) the upstream support portion is disposed against the upstream side of the native valve, (2) the first clip is coupled to the first leaflet, and (3) the second clip is coupled to the second leaflet, the first clip moves toward the second clip during ventricular systole of the subject, and moves away from the second clip during ventricular diastole of the subject.


In an application, the clip is flexibly coupled to the upstream support portion.


In an application, the clip is coupled to the upstream support portion via a flexible connector, the flexible connector having a length from the upstream support portion to the clip, and the length of the flexible connector is variable.


In an application, the upstream support portion is generally flat.


In an application, the inner perimeter defines the opening, such that the opening has a depth and a width, and the width of the opening is more than four times greater than the depth of the opening.


In an application, the upstream support portion has a free inner edge, and the free inner edge defines the inner perimeter.


In an application, the inner perimeter defines an opening that has a diameter, and the upstream support portion has a diameter that is at least 10 percent greater than the diameter of the opening.


In an application, no part of the prosthetic valve support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 20 mm.


There is further provided, in accordance with an application of the present invention, apparatus for facilitating implantation of a prosthetic valve at a native heart valve of a subject, the native heart valve including a native annulus and a plurality of native leaflets that provide check valve functionality, the apparatus including a prosthetic valve support, the prosthetic valve support:


being configured to be transluminally-delivered to the native valve and to be deployed at the native valve, and


including one or more tissue-engaging elements, configured to couple the prosthetic valve support to the native leaflets without eliminating the check valve functionality.


In an application, the tissue-engaging elements are configured to couple the prosthetic valve support to the native leaflets without eliminating the check valve functionality, by coupling the prosthetic valve support to the native leaflets such that:


the native leaflets define a single orifice therebetween, and


the native valve functions as a single check valve.


In an application, the tissue-engaging elements include at least a first tissue-engaging element and a second tissue-engaging element, and the first tissue-engaging element is transluminally controllable independently of the second tissue-engaging element.


In an application, the tissue-engaging elements are configured to couple the prosthetic valve support to the native leaflets without eliminating the check valve functionality, by coupling the prosthetic valve support to the native leaflets such that:


the native leaflets define two orifices therebetween, and


the native valve functions as two check valves.


In an application:


the native leaflets include a first leaflet and a second leaflet,


the tissue-engaging elements include at least a first tissue-engaging element and a second tissue-engaging element,


the first tissue-engaging element is configured to be coupled to a portion of the first leaflet, and


the second tissue-engaging element is configured to be coupled to a portion of the second leaflet and to the first tissue-engaging element.


In an application, the apparatus is configured such that the first tissue-engaging element is transluminally, intracorporeally decouplable from the second tissue-engaging element.


In an application, the prosthetic valve support includes an annular upstream support portion:


shaped to define an opening therethrough,


coupled to the tissue-engaging elements,


configured to be placed against an upstream surface of the native annulus, and


configured to be transluminally, intracorporeally, coupled to the prosthetic valve.


In an application, the apparatus further includes the prosthetic valve, and the prosthetic valve includes a flexible netting at at least an upstream portion of the prosthetic valve, and the netting is configured to facilitate coupling of the prosthetic valve to the upstream support portion.


In an application, the prosthetic valve support includes one or more flexible connectors, and each tissue-engaging element is flexibly coupled to the upstream support portion by a respective flexible connector.


In an application, each flexible connector has a length, and is configured such that the length is variable while the tissue-engaging elements are coupled to the native leaflets.


In an application, the upstream support portion has a compressed configuration and an expanded configuration, and is configured (1) to be delivered to the native valve in the compressed configuration, and (2) to be expanded into the expanded configuration at the native valve.


In an application, the apparatus further includes one or more coupling leads, and the apparatus is configured such that the expansion of the upstream support portion is controllable using the coupling leads.


In an application, each coupling lead passes around at least a portion of the upstream support portion, and the apparatus is configured such that the upstream support portion is recompressible from the expanded configuration toward the compressed configuration, by pulling on the coupling leads.


In an application, the prosthetic valve support includes a downstream stabilizing element:


shaped to define an opening therethrough,


coupled to the tissue-engaging elements,


configured to be placed entirely downstream of the native annulus, and


configured to be coupled to the prosthetic valve.


In an application, the apparatus further includes the prosthetic valve, and the prosthetic valve includes a valve body and one or more valve-anchoring elements, the valve-anchoring elements being configured to sandwich the downstream stabilizing element between the valve-anchoring elements and the valve body.


In an application, the prosthetic valve support is configured to be coupled to the native leaflets such that no portion of the prosthetic valve support is disposed upstream of the native annulus.


In an application, the tissue-engaging elements include clips, each clip including a plurality of clip arms, including at least a first clip arm and a second clip arm, and configured to couple at least a portion of one of the native leaflets between the first and second clip arms.


In an application, the apparatus further includes a clip controller, configured to be advanced transluminally to the native valve, and each clip includes a clip-controller interface, configured to be reversibly coupled to the clip controller, and to facilitate extracorporeal control of the clips independently of deployment of the prosthetic valve support.


In an application, each clip is configured such that movement of at least a portion of the clip-controller interface by a first distance, changes a distance between a portion of the first clip arm and a portion of the second clip arm by a second distance that is more than 1.5 times greater than the first distance.


In an application, the tissue-engaging elements are configured to suturelessly couple the prosthetic valve support to the native leaflets.


In an application, the prosthetic valve support is configured to be transluminally, intracorporeally, couplable to the prosthetic valve.


There is further provided, in accordance with an application of the present invention, a method for use at a native valve of a subject, the native valve including at least one native leaflet that provides native check valve functionality, the method including:


transluminally delivering a prosthetic valve support to the native valve;


coupling a prosthetic valve support to the leaflet of the native valve without eliminating the native check valve functionality; and


subsequently, replacing, at least in part, the native check valve functionality with a substitute check valve functionality, by coupling a prosthetic valve to the prosthetic valve support.


In an application:


the prosthetic valve support includes at least one clip,


the clip includes two or more clip arms and a clip-controller interface, and


coupling the prosthetic valve support to the leaflet includes changing an angular disposition between the clip arms by moving the clip-controller interface.


There is further provided, in accordance with an application of the present invention, apparatus for use with a native heart valve of a subject, the apparatus including:


a first expandable prosthetic valve component, including a crimpable frame, and configured to be transcatheterally advanceable toward the native valve while the first prosthetic valve component is in a crimped state thereof;


a second expandable prosthetic valve component, including a crimpable frame, and configured to be transcatheterally advanceable toward the native valve, placeable in the native valve while the second prosthetic valve component is in a crimped state thereof, and couplable to the first prosthetic valve component, expansion of the second prosthetic valve component facilitating coupling of the second prosthetic valve component to the first prosthetic valve component; and


one or more tissue-engagement elements, coupled to at least one of the prosthetic valve components, the tissue-engagement elements configured, when the prosthetic valve component is in an expanded state thereof, to extend from the prosthetic valve component, and to inhibit a proximal movement of the prosthetic valve component.


There is further provided, in accordance with an application of the present invention, apparatus for use with a prosthetic valve for implantation at a native valve of a subject, the native valve (1) defining an orifice, (2) including at least one native leaflet, having a native beating, and (3) having a native blood flow regulation functionality, the apparatus including:

    • a prosthetic valve support, including:
    • an upstream support portion, configured to be placed against an upstream side of the native valve, to have an inner perimeter that defines an opening that is configured to receive the prosthetic valve, and
      • at least one clip, configured to be coupled to a native leaflet of the native valve, the clip including a plurality of clip arms, at least one clip arm coupled to a clip-controller interface; and
    • a clip controller, couplable to the clip-controller interface, and configured to control a relative angular disposition between the clip arms.


For some applications, techniques described herein are practiced in combination with techniques described in one or more of the references cited in the Background section and Cross-references section of the present patent application.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-D are schematic illustrations of apparatus, comprising a prosthetic valve support, for facilitating implantation of a prosthetic heart valve at a native heart valve of a subject, in accordance with some applications of the invention;



FIGS. 2A-D are schematic illustrations of the prosthetic valve support, and components thereof, in accordance with respective applications of the invention;



FIGS. 3A-I are schematic illustrations of steps in the delivery and implantation of the prosthetic valve support at the native heart valve of the subject, and the use thereof to facilitate implantation of the prosthetic valve, in accordance with some applications of the invention;



FIGS. 4A-F are schematic illustrations of a system for facilitating controlled expansion and/or retrievability of an upstream support portion of the prosthetic valve support, in accordance with some applications of the invention;



FIG. 5 is a schematic illustration of a step in the implantation of the prosthetic valve support, in accordance with some applications of the invention;



FIGS. 6A-B are schematic illustrations of a prosthetic valve support comprising tissue-engaging elements that are couplable to each other, and decouplable from each other, in accordance with some applications of the invention;



FIG. 7 is a schematic illustration of a prosthetic valve support comprising the upstream support portion and three clips, in accordance with some applications of the invention;



FIG. 8 is a schematic illustration of a step in the implantation of the prosthetic valve, facilitated by the prosthetic valve support, in accordance with some applications of the invention; and



FIGS. 9A-C are schematic illustrations of the prosthetic valve support comprising variable-length connectors, in accordance with respective applications of the invention.





DETAILED DESCRIPTION OF EMBODIMENTS

Reference is made to FIGS. 1A-D, which are schematic illustrations of apparatus 20, comprising a prosthetic valve support 22 for facilitating implantation of a prosthetic heart valve at a native heart valve of a subject, in accordance with some applications of the invention. Prosthetic valve support 22 comprises one or more tissue-engaging elements 24 (e.g., support-anchoring elements), and is typically configured to be coupled to the native heart valve (e.g., to leaflets thereof) without eliminating check valve functionality of the native heart valve (described in more detail hereinbelow). Typically, prosthetic valve support 22 is configured to be transluminally, intracorporeally coupled to the native heart valve.


Typically, each tissue-engaging element 24 comprises a clip 30, which typically comprises a plurality of clip arms 32 (e.g., two clips arms, e.g., a first clip arm 32a and a second clip arm 32b), the clip being configured to be coupled to a leaflet of the native valve. Clip arms 32a and 32b are movable with respect to each other, thereby opening and closing clip 30 (e.g., moving clip 30 between an open state and a closed state thereof), e.g., as shown in FIG. 1B. Clip arms 32a and 32b are typically articulatably coupled to each other at an articulation point 31 (e.g., a coupling point), such that opening and closing clip 30 comprises changing a relative angular disposition between the clip arms. Typically, each clip arm 32 has a length from a first end thereof, at which the clip arms are coupled to each other (e.g., at articulation point 31), to a second end thereof, of greater than 1.5 mm and/or less than 20 mm (e.g., between 3 and 10 mm). For some applications, a length d7 of clip arm 32a is generally the same as a length d8 of clip arm 32b (e.g., as shown in FIG. 1B). For some applications, length d8 of clip arm 32b is shorter than length d7 of clip arm 32a (e.g., at least 30% shorter, such as at least 50% shorter), e.g., so as to reduce force applied to the leaflet of the native valve by clip arm 32b (such as by the second end of the clip arm).


For some applications of the invention, at least one of the clip arms (e.g., clip arm 32b) comprises a tissue-engaging portion 48 that is articulatably coupled to another portion of the clip arm at an articulation point 47, such that, at a given relative angular disposition of clip arms 32a and 32b (e.g., a degree of openness of clip 30), a relative angular disposition of portion 48 with respect to clip arm 32a, may change (e.g., may be changed). For example, for at least some states of clip 30, the relative angular disposition of clip arm 32a and portion 48 may be generally independent of the relative angular disposition of clip arm 32a and the other portion of clip arm 32b. For example, portion 48 may remain parallel with clip arm 32a, irrespective of the angular disposition of clip arms 32a and 32b. It is hypothesized that this configuration facilitates coupling of clip 30 to the leaflet of the native valve, by allowing the clip to maintain contact with both sides of the leaflet, irrespective of dimensions (e.g., thicknesses) of the leaflet to which clip 30 is coupled.


Prosthetic valve support 22 is typically configured to be implanted using minimally-invasive procedures (e.g., percutaneously). Further typically, the prosthetic valve support is configured to be delivered transluminally (e.g., transfemorally). Alternatively, the prosthetic valve support may be configured to be delivered transthoracically (e.g., transapically). Typically, the prosthetic valve support is configured in this way by being compressible (e.g., crimpable) into a delivery configuration, and by being configured to expand (e.g., automatically) upon deployment at the native valve. Typically, tissue-engaging elements 24 (e.g., clips 30) are coupled to the leaflets of the native valve before prosthetic valve support 22 is fully deployed, such as while at least part of the prosthetic valve support remains within a delivery tube (e.g., as shown in FIGS. 3B-C).


Clips 30 are typically configured to be controllable (i.e., openable and closable) independently of each other, and/or independently of deployment of prosthetic valve support 22 (e.g., irrespective of a state of deployment of the prosthetic valve support, such as irrespective of a state of expansion of an upstream support portion 60 of the prosthetic valve support, described hereinbelow).


Clip 30 typically further comprises a clip-controller interface 34, which is configured to facilitate control (e.g., opening and closing) of the clip from outside the subject (i.e., to facilitate extracorporeal control of the clip), e.g., by a physician. Clip-controller interface 34 is reversibly couplable to a clip controller 36, which is itself extracorporeally controllable, e.g., by extending from outside the subject to the clip-controller interface. Clip 30 is thereby typically transluminally controllable. Typically, clip controller 36 facilitates control of the clip by applying a force to clip-controller interface 34, e.g., by transferring an extracorporeally-applied force to the clip-controller interface. Typically, clip controller 36 is integral with delivery apparatus that is used to deliver support 22 to the native valve (e.g., delivery apparatus 140, described hereinbelow with reference to FIGS. 3A-D).


Clip-controller interface 34 is typically articulatably coupled to at least clip arm 32b (e.g., at an articulation point 35), and/or comprises one or more articulatably coupled portions (e.g., a first interface portion 34a and a second interface portion 34b). Clips 30 are typically configured such that movement of clip-controller interface 34 by a first distance d1, moves clip arm 32b by a second distance d2 that is typically more than 1.5 times (e.g., more than 2 times, such as more than 4 times) greater than distance d1. That is, a relatively large range of movement of clip arm 32b is provided by a relatively small range of movement of clip-controller interface 34, e.g., clip-controller interface 34, clip arm 32b, and/or the coupling therebetween, acts as a lever. Clip 30 is typically configured such that clip arm 32b can articulate over more than 60 degrees, e.g., more than 100 degrees, such as up to 180 degrees, around articulation point 31, with respect to clip arm 32a.


It is hypothesized that, for some applications, angles of articulation greater than 80 degrees (e.g., greater than 120 degrees, such as up to 180 degrees) facilitate (1) repeated coupling to, and decoupling from, the native leaflets (e.g., multiple attempts to couple to the native leaflets), and (2) retrieval of the clips and/or the entire prosthetic valve support (e.g., into a delivery tube).


Clip-controller interface 34 (e.g., portion 34a thereof) is typically slidably coupled to at least clip arm 32a. That is, moving of clip-controller interface 34 typically includes sliding of the clip-controller interface with respect to clip arm 32a (e.g., by using clip controller 36).


For some applications of the invention, at least one of clip arms 32 comprises or defines grips 38 and/or teeth 40, which are configured to facilitate coupling of clip 30 to a native leaflet of the native valve. Typically, grips 38 are configured to atraumatically grip the leaflet and teeth 40 are configured to grip, fold around, and/or pierce the leaflet. For some applications of the invention, at least a portion of clip arms 32 is covered with a padding (not shown), configured to cushion the contact between the clip arms and the leaflet.


Typically, clip 30 is lockable, such that clip arm 32b is locked (e.g., immobile) with respect to clip arm 32a. FIGS. 1B-D show clip 30 comprising a locking element 50 (e.g., a securing element), which facilitates locking of the clip. Locking element 50 typically comprises at least one ratchet mechanism 52, comprising (1) a rack 51, comprising a plurality of sockets 54, and (2) an engaging element 56 (e.g., a pawl, or a tooth). Typically, rack 51 is defined by, or is fixedly coupled to, clip arm 32a, and engaging element 56 is coupled to, or defined by, clip-controller interface 34. However, the scope of the invention includes other (e.g., inverse) arrangements of ratchet mechanism 52.



FIG. 1B shows clip 30 in an unlocked configuration thereof, in which an obstructing element 58 (e.g., a restraint) is disposed between rack 51 and engaging element 56, thereby inhibiting (e.g., obstructing) engaging element 56 from engaging rack 51, and thereby facilitating the opening and closing of the clip (i.e., movement between open and closed states thereof). Typically, obstructing element 58 is integral with delivery apparatus that is used to deliver support 22 to the native valve (e.g., delivery apparatus 140, described hereinbelow with reference to FIGS. 3A-D). FIG. 1B shows a front view and a back view of clip 30 in the open state thereof, and a front view and a back view of the clip in the closed state thereof.



FIG. 1C shows a back view of clip 30 in a locked configuration thereof, in which obstructing element 58 has been removed from between rack 51 and engaging element 56 (e.g., by withdrawing the obstructing element proximally), and an engaging element 56 has engaged the rack. Typically, element 56 is configured (e.g., shape-set) to automatically engage rack 51 upon removal of obstructing element 58.


For some applications, and as shown in FIGS. 1B-D, obstructing element 58 comprises a longitudinal member, such as a strip or rod, and is removed by being withdrawn proximally. However, obstructing element 58 may have other shapes and/or shape-memory features that facilitate the obstruction of engaging element 56 and/or the removal of the obstructing element. For example, obstructing element 58 may have a generally circular, rectangular, triangular, or hexagonal cross-section, and/or may be shape-set to facilitate removal thereof, and thereby to facilitate locking of the clip.


For some applications of the invention, and as shown in FIGS. 1B-D, locking element 50 comprises two ratchet mechanisms 52. The two ratchet mechanisms are offset with respect to the other, such that at a position of clip-controller interface 34 in which the engaging element 56 of one ratchet mechanism is fully disposed in a socket 54, the engaging element of the other ratchet mechanism is not fully disposed in a socket of the other rack (FIGS. 1C-D). This configuration increases (e.g., doubles) the number of positions within a given range in which clip-controller interface 34 is lockable, without reducing the size of each socket 54. That is, this configuration increases the “resolution” or “density” of locking positions of clip 30. It is hypothesized that, for some applications, it is advantageous to combine this configuration of locking element 50 with the lever-like clip-controller interface described hereinabove, such that the relatively large movement of clip arm 32b is at least partly offset by the “high resolution” of the locking element, thereby increasing the degree of control that the physician has on the clip.


As described hereinabove, clip-controller interface 34 is typically reversibly couplable to clip controller 36. Typically, this reversible coupling is facilitated by a projection 42, defined by clip controller 36, which is configured to be disposed within, and removed from, a depression 44, defined by clip-controller interface 34. Further typically, projection 42 is configured (e.g., shape-set) to move out from depression 44, and is prevented from moving out of depression 44 by obstructing element 58. Following the locking of clip 30 by withdrawing obstructing element 58 (FIG. 1C), the obstructing element is further withdrawn (FIG. 1D), thereby releasing projection 42 from depression 44, and thereby decoupling clip controller 36 from clip-controller interface 34. Clip 30 is typically configured such that the physician may repeatedly lock and unlock clip 30 (e.g., by partially withdrawing and replacing obstructing element 58) before finally decoupling the controller (e.g., by completely withdrawing obstructing element 58), such as after confirming that clip 30 has been successfully coupled to the native leaflet.


As described hereinabove, clips 30 are typically configured to be controllable (i.e., openable and closable) independently of each other, and/or independently of deployment of prosthetic valve support 22. Clips 30 are further typically lockable and/or decouplable from controller 36 independently of each other, and/or independently of deployment of the prosthetic valve support. It is to be noted that clips 30 are configured to couple the prosthetic valve support to the native leaflets suturelessly.


Referring again to FIG. 1A, prosthetic valve support 22 typically comprises a generally annular upstream support portion 60 (e.g., an annular portion), shaped to define an opening 61 (e.g., an aperture) therethrough, and to be placed against an upstream side of the native valve. Typically, upstream support portion 60 comprises an expandable lattice-structure frame 62 (e.g., comprising a plurality of struts), covered by a covering 64. Opening 61 is defined by an inner perimeter 68 of the prosthetic valve support. For some applications, frame 62 defines a plurality of barbs 67 that protrude radially inwardly from inner perimeter 68, and facilitate coupling of a prosthetic valve to the prosthetic valve support (e.g., as described hereinbelow with reference to FIGS. 3H-I).


Upstream support portion 60 typically has shape-memory (e.g., resilient, pseudoelastic and/or superelastic) properties. Typically, frame 62 comprises a shape-memory (e.g., resilient, pseudoelastic and/or superelastic) material, such that upstream support portion 60 is compressible (e.g., crimpable) when a compressive force is applied (e.g., prior to implantation), and re-expandable when the compressive force is removed (e.g., during implantation). Non-limiting examples of materials that frame 62 may comprise, include nickel-titanium (nitinol), stainless steel, nickel cobalt, cobalt chrome, titanium, tantalum, and palladium.


Non-limiting examples of materials that covering 64 may comprise, include polyethylene terephthalate (e.g., polyester), polytetrafluoroethylene (e.g., Teflon, ePTFE), and pericardial tissue. For some applications, covering 64 comprises a fabric. Typically, a thickness of the covering is less than 0.5 mm, such as less than 0.2 mm, e.g., less than 0.1 mm, or less than 0.05 mm.



FIG. 1A shows upstream support portion 60 in an expanded (e.g., fully uncompressed and/or deployed) configuration thereof, in which upstream support portion 60 (i.e., an outer perimeter 69 thereof) typically has a diameter d3 that is greater than 40 mm and/or less than 80 mm (e.g., 40-80 mm, such as 40-70 mm, such as 40-60 mm). That is, an outer diameter of upstream support portion 60 is typically greater than 40 mm and/or less than 80 mm (e.g., 40-80 mm, such as 40-70 mm, such as 40-60 mm). Opening 61, defined by inner perimeter 68, typically has a diameter d4 of greater than 20 mm and/or less than 35 mm (e.g., 20-35 mm, such as 23-32 mm, such as 25-30 mm). That is, an inner diameter of upstream support portion 60 is typically greater than 20 mm and/or less than 35 mm (e.g., 20-35 mm, such as 23-32 mm, such as 25-30 mm). Typically, diameter d3 is at least 10% (e.g., at least 50%, such as at least 80%) greater than diameter d4.


Upstream support portion 60 is typically compressible (e.g., crimpable; for delivery to the native valve) into a generally cylindrical shape in which inner perimeter 68 defines a downstream end 71 of the cylindrical shape, and outer perimeter 69 defines an upstream end 73 of the cylindrical shape (see FIG. 3A). Typically, the generally cylindrical shape of upstream support portion 60 has a transverse cross-sectional diameter (e.g., a width) of greater than 3 mm and/or less than 9 mm (e.g., 3-9 mm, such as 5-8 mm, such as 6-7 mm), and a height, from the upstream end to the downstream end, of greater than 11 mm and/or less than 30 mm (e.g., 11-30 mm, such as 15-30 mm, such as 15-25 mm).


In the expanded configuration thereof, upstream support portion 60 is typically (but not necessarily) generally flat (e.g., laminar, and/or planar). For some applications, in the expanded configuration, upstream support portion 60 assumes a frustoconical shape. Upstream support portion 60 typically has a thickness of less than 5 mm, e.g., less than 2 mm, such as between 0.3 mm and 2 mm. Inner perimeter 68 (and thereby opening 61) thereby typically has a depth d10 (e.g., a height) from an upstream side 59 of the upstream support portion to a downstream side 63 of the upstream support portion. Depth d10 is less than 5 mm, e.g., less than 2 mm, such as between 0.3 mm and 2 mm. Typically, diameter d4 of opening 61 is more than 4 times (e.g., more than 6 times, such as more than 10 times) greater than depth d10. That is, opening 61 is more than 4 times (e.g., more than 6 times, such as more than 10 times) wider than it is deep. Typically, in the expanded configuration, upstream support portion 60 has a total height of less than 10 mm (e.g., less than 5 mm, such as less than 2 mm).


Typically, inner perimeter 68 comprises, or is defined by, a free inner edge of upstream support portion 60. That is, opening 61 resembles a hole cut out of a lamina (e.g., out of a disc). For some applications, inner perimeter 68 comprises, or is defined by, a curved and/or folded inner edge of upstream support portion 60. If the inner perimeter of upstream support portion 60 comprises, or is defined by, a curved or folded edge, then a radius of curvature of the curved or folded edge is typically less than 2.5 mm, such as less than 1 mm. That is, the curve or fold of the edge is generally sharp, such that when viewed from within opening 61, the curved or folded edge looks generally like a free edge.


Prosthetic valve support 22 typically comprises two or more tissue-engaging elements 24 (e.g., clips 30), coupled to inner perimeter 68 of upstream support portion 60. For such applications, the two tissue-engaging elements are typically disposed opposite each other (e.g., at 180 degrees around inner perimeter 68 from each other).


Typically, tissue-engaging elements 24 (e.g., clips 30) are coupled to upstream support portion 60 (e.g., inner perimeter 68 thereof) by a flexible connector 70, which may comprise polyethylene terephthalate (e.g., polyester), polytetrafluoroethylene (e.g., Teflon, ePTFE), a fabric, nitinol, and/or any other suitable material. Thereby, tissue-engaging elements 24 (e.g., clips 30) are typically flexibly coupled to upstream support portion 60, and/or are able to move independently of each other. Connector 70 may be coupled to upstream support portion 60 and tissue-engaging elements 24 using sutures, welding, and/or any other suitable technique known in the art.


Prosthetic valve support 22 typically further comprises a stabilizing element 80, coupled to clips 30 (e.g., to a downstream portion thereof). Typically, stabilizing element 80 forms a ring shape that defines an opening 81 (e.g., an aperture), and is typically inelastic and at least partly flexible. Opening 81 typically, but not necessarily, has a diameter that is generally equal to diameter d4 of opening 61. Non-limiting examples of materials that stabilizing element 80 may comprise include polyethylene terephthalate (e.g., polyester), PTFE (e.g., ePTFE), nylon, cotton, nitinol, stainless steel, nickel cobalt, cobalt chrome, titanium, tantalum and palladium. Typically, and as shown in FIG. 1A, stabilizing element 80 comprises (1) an outer coat 82 of a flexible material (e.g., polyester), which typically provides inelasticity, and (2) an inner strip 84 of a shape-memory material (e.g., nitinol), which is typically configured (e.g., shape-set) to bias element 80 to assume a ring-shaped configuration.


Stabilizing element 80 (and thereby opening 81) typically has a depth d11 (e.g., a height from a most upstream part to a most downstream part) of less than 20 mm (e.g., less than 10 mm, e.g., less than 5 mm, such as less than 1 mm). As described hereinabove, inner perimeter 68 of upstream support portion has a depth d10 of less than 5 mm. Typically, in the expanded configuration, no part of prosthetic valve support 22 that circumscribes a space that has a perimeter greater than 60 mm (e.g., as upstream support portion 60 and stabilizing element 80 typically do) has a height of more than 20 mm. For some applications, in the expanded configuration, no part of the support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 10 mm. For some applications, in the expanded configuration, no part of the support that circumscribes a space that has a perimeter greater than 60 mm has a height of more than 5 mm.


Reference is made to FIGS. 2A-D, which are schematic illustrations of prosthetic valve support 22 and/or components thereof, in accordance with respective applications of the invention. As described hereinabove, upstream support portion 60 is generally annular. For some applications, and as shown in FIG. 1A, upstream support portion 60 has a generally circular outer perimeter 69. FIG. 2A shows an alternative embodiment in which upstream support portion 60 comprises an upstream support portion 90, which has a non-circular outer perimeter 99. FIG. 2A shows outer perimeter 99 as generally oval, with a “squashed” portion 92. Such a configuration may, for example, facilitate placement of upstream support portion 90 at a mitral valve of the subject, with squashed portion 92 facing the interatrial septum. It is to be noted, that the scope of the invention includes upstream support portions having other shapes, configured according to the anatomical site at which they are to be placed. For example, for some applications, upstream support portion 60 and/or upstream support portion 90 may have radially-protruding bulges or wings (not shown), configured to stabilize the upstream support portion and/or to inhibit leakage between the native valve and the upstream support portion.


As described hereinabove, upstream support portion 60 typically comprises an expandable lattice-structure frame 62. FIG. 2B shows an alternative embodiment in which upstream support portion 60 comprises a braided upstream support portion 100, which comprises a braided structure of intertwining strands 102, at least some of which are slidable past (e.g., over, under) each other. Typically, strands 102 comprise a shape-memory material such as, but not limited to, nitinol. Upstream support portion 100 is transluminally deliverable in a compressed configuration, and is expandable to an annular, expanded configuration at the native valve. Typically, support 100 is configured to automatically expand to the expanded configuration, and this expansion is controlled by progressively releasing (e.g., loosening and/or unthreading) a restricting element 104 (e.g., a drawstring), which, when threaded through parts of upstream support portion 100 (e.g., one or more rings 106 thereof), is configured to restrict expansion of the upstream support portion (e.g., to retain the upstream support portion in the compressed configuration thereof). FIG. 2B shows sequential stages in the deployment of upstream support portion 100 from a delivery tube 108. Typically, upstream support portion 100 is recompressible by tightening (e.g., pulling) the restricting element.


As described hereinabove, prosthetic valve support 22 comprises one or more tissue-engaging elements 24, and typically further comprises upstream support portion 60 and/or stabilizing element 80. FIG. 1A shows prosthetic valve support 22 comprising both upstream support portion 60 and stabilizing element 80. FIG. 2C shows an alternative embodiment in which prosthetic valve support 22 comprises a prosthetic valve support 322, which does not comprise stabilizing element 80. FIG. 2D shows an alternative embodiment in which prosthetic valve support 22 comprises a prosthetic valve support 422, which does not comprise an upstream support portion (e.g., upstream support portion 60). For some applications of the invention, when implanted at the native valve, no portion of prosthetic valve support 422 is disposed upstream of the native annulus.


It is to be noted that upstream support portions 90 and 100, and prosthetic valve supports 322 and 422, may be used (e.g., combined) with apparatus and methods described elsewhere herein. For example, the upstream support portion of any of the prosthetic valve supports described herein may be replaced with upstream support portion 90 or upstream support portion 100, resulting in alternative prosthetic valve supports. Furthermore, these resulting prosthetic valve supports, as well as prosthetic valve supports 322 and 422, may be used in combination with other techniques described herein (e.g., with reference to FIGS. 3A-I, 4A-F, 5, 6A-B, 7, 8, and/or 9A-C), mutatis mutandis.


Reference is made to FIGS. 3A-I, which are schematic illustrations of steps in the delivery and implantation of prosthetic valve support 22 at a native heart valve 120 of heart 250 of a subject, and the use thereof to facilitate implantation of a prosthetic valve 150, in accordance with some applications of the invention. FIGS. 3A-I show native valve 120 as comprising a mitral valve 122 of the subject, but it is to be noted that the scope of the invention includes the use of prosthetic valve support 22 at other heart valves of the subject.


Mitral valve 122 is disposed between a left atrium 124 and a left ventricle 126 of the subject, and comprises two leaflets 128. Atrium 124 is upstream of mitral valve 122 and ventricle 126 is downstream of the mitral valve. Prosthetic valve support 22, in a compressed configuration thereof, is advanced transluminally (e.g., transfemorally and/or transseptally) within a delivery tube 130 of delivery apparatus 140, to atrium 124, and between leaflets 128 (FIG. 3A).


Prosthetic valve support 22 is advanced out of delivery tube 130 and/or the delivery tube is withdrawn from the prosthetic valve support (FIG. 3B). Clips 30 (and/or other tissue-engaging elements) are typically disposed at a downstream portion of prosthetic valve support 22 (e.g., downstream of downstream end 71 of upstream support portion 60) in the compressed configuration thereof, and are thereby exposed from delivery tube 130. Stabilizing element 80 is also typically exposed from the delivery tube, and typically forms a generally lemniscate (e.g., figure-8) shape, defining two “loops” 83. Typically, the axis between loops 83 of the lemniscate is generally orthogonal to the axis between clips 30, and may be used to orient prosthetic valve support 22, e.g., such that clips 30 point toward leaflets 128 of the native valve. For example, loops 83 may be disposed between chordae tendineae 72 of one leaflet and those of the other leaflet, and physical contact between the chordae tendineae and the loops automatically and/or via tactile feedback to the physician, facilitates orientation of the prosthetic valve support. Alternatively or additionally, the lemniscate shape of stabilizing element 80 may be visualized using imaging techniques such as fluoroscopy and/or ultrasound. Clips 30 are opened (e.g., as described hereinabove with reference to FIG. 1B).


Prosthetic valve support 22 is moved upstream (e.g., proximally) so as to envelope leaflets 128 between clip arms 32 of each clip 30, and each clip is closed around a leaflet, thereby coupling each clip to a leaflet, e.g., by clamping the leaflet between the clip arms (FIG. 3C). Each clip 30 couples to a single leaflet 128, such that one clip arm of each clip (e.g., clip arm 32a) engages an upstream surface of the leaflet (e.g., an upstream side of the leaflet), and the other clip arm of each clip (e.g., clip arm 32b) engages a downstream surface of the leaflet (e.g., a downstream side of the leaflet). Although each clip typically couples to only one leaflet, for some applications, more than one clip couples to each leaflet.


As described hereinabove, clips 30 (and/or other tissue-engaging elements 24) are typically coupled to the leaflets of the native valve before prosthetic valve support 22 is fully deployed. Clips 30 are typically locked (e.g., as described with reference to FIG. 1C), and subsequently decoupled from clip controller 36 (e.g., as described with reference to FIG. 1D). FIGS. 3C-F show stages in the deployment of prosthetic valve support 22 (e.g., of upstream support portion 60 thereof). Upstream support portion 60 typically progressively expands as it is exposed from delivery tube 130. Thereby, typically, (1) downstream end 71 of the cylindrical shape of the upstream support portion in the compressed configuration thereof, expands to become inner perimeter 68 of the upstream support portion in the expanded configuration thereof, and (2) subsequently, upstream end 73 of the cylindrical shape expands to become outer perimeter 69 of the upstream support portion.


Delivery apparatus 140 typically comprises a pushing member 132. Typically, prosthetic valve support 22 (e.g., upstream support portion 60 thereof) is reversibly coupled to pushing member 132, and is exposed from delivery tube 130 by being pushed using the pushing member. Upstream support portion 60 is typically configured (e.g., shape-set) to automatically expand toward its expanded configuration upon being deployed from delivery tube 130. For some applications of the invention, the upstream support portion “pops” open from the configuration shown in FIG. 3C to the configuration shown in FIG. 3F, immediately upon exposure of upstream end 73 of the upstream support portion from delivery tube 130.


For some applications, and as shown in FIGS. 3C-F, one or more holding members 134, coupled to, and decouplable from, upstream support portion 60, facilitate controlled expansion of the upstream support portion. For example, holding members 134 may be configured to allow a physician (1) to expand some portions of the upstream support portion before other portions and/or (2) to adjust the positioning of the upstream support portion on the upstream surface of the native valve following expansion of the upstream support portion. For some applications, two holding members 134 are used, and are coupled to opposite sides of upstream support portion 60 to each other (e.g., 180 degrees around the upstream support portion from each other).


For some applications, and as shown in FIGS. 3D-F, three holding members 134 are used. For such applications, each holding member 134 is coupled at between 90 and 180 degrees (e.g., between 100 and 150 degrees, such as at 120 degrees) around the upstream support portion from the other holding members. For some such applications, and as shown in FIG. 3F, the holding members are coupled to the upstream support portion such that, when the upstream support portion is positioned at the native valve, two holding members are disposed generally above respective commissures of the native valve, and the third holding member is disposed generally midway around posterior leaflet 128p of the native valve.


For some applications, holding members 134 comprise locking elements and/or coupling leads (e.g., coupling wires, e.g., looped around respective portions of the upstream support portion; not shown in FIGS. 3D-F) that couple the holding members to the upstream support portion, and the holding members are decoupled from the upstream support portion by unlocking the locking elements and/or unlooping the loops. For some applications of the invention, holding members 134 also facilitate retrieval of the upstream support portion, and thereby of prosthetic valve support 22, e.g., as described with reference to FIGS. 4A-F.



FIG. 3G shows prosthetic valve support 22 following coupling, deployment and expansion (i.e., implantation) thereof at mitral valve 122, and withdrawal of delivery apparatus 140. As described hereinabove, prosthetic valve support 22 is configured to be coupled to the native heart valve (e.g., to leaflets thereof) without eliminating check valve functionality of the native heart valve. Typically, and as shown in FIG. 3G, clips 30 couple the prosthetic valve support to leaflets 128 such that (1) the leaflets define a single orifice, and (2) the native valve functions as a single check valve (e.g., functions in a manner that is generally similar to the natural (e.g., physiological) function of the native valve). Stabilizing element 80 is also configured to allow such movement of leaflets 128, e.g., the stabilizing element is sufficiently flexible to flex in response to the leaflets moving in response to pumping of the heart. FIG. 3G shows (1) in solid, mitral valve 122 (e.g., leaflets 128) closed, and the respective state of prosthetic valve support 22, and (2) in phantom, the mitral valve (e.g., the leaflets) open, and the respective state of the prosthetic valve support.


Thereby, when prosthetic valve support 22 is implanted at an atrioventricular valve of the subject (e.g., mitral valve 122 or a tricuspid valve), clips 30 typically move away from each other during ventricular diastole, and toward each other during ventricular systole. For applications in which prosthetic valve support 22 is implanted at a native semilunar valve of the subject (e.g., an aortic valve or a pulmonary valve), clips 30 typically move toward each other during ventricular diastole, and away from each other during ventricular systole.


Subsequently (e.g., immediately subsequently, or after more than a minute, e.g., after more than 2 minutes, e.g., after more than 5 minutes, such as after more than an hour), a prosthetic valve 150 is transluminally delivered, in a compressed configuration thereof (e.g., within a delivery tube 160), to the native valve, and implanted at the native valve by coupling the prosthetic valve to prosthetic valve support 22. Implantation of prosthetic valve 150 replaces check valve functionality of the native valve with a substitute check valve functionality of the prosthetic valve. The substitute check valve functionality is provided by one or more prosthetic check valve elements (e.g., valve members, such as leaflets, a ball, or a disc), such as those known in the art, which the prosthetic valve comprises (not shown).


Typically, and as shown in FIG. 3H, respective portions of prosthetic valve 150 are placed within opening 61 (defined by upstream support portion 60) and/or opening 81 (defined by stabilizing element 80), and are expanded such that the respective portions engage the upstream support portion and the stabilizing element, respectively. Typically, prosthetic valve 150 is configured to automatically expand upon deployment from delivery tube 160, and radially-expansive force applied by prosthetic valve 150 to upstream support portion 60 and/or stabilizing element 80 facilitates coupling of the prosthetic valve to prosthetic valve support 22.



FIG. 3I shows prosthetic valve 150 having been fully deployed and coupled to prosthetic valve support 22. That is, FIG. 3I shows an implant 180, comprising prosthetic valve support 22 and prosthetic valve 150, having been implanted at native valve 120 (e.g., at mitral valve 122). Prosthetic valve 150 is described in more detail hereinbelow.


Typically, diameter d3 of upstream support portion 60 is greater than a diameter d5 of the native valve (e.g., a diameter of the orifice of the native valve, e.g., an inner diameter of the annulus of the native valve). Further typically, diameter d4 of opening 61 is smaller than diameter d5. When prosthetic valve 150 is expanded within opening 61 of the upstream support portion, a diameter d6 of the prosthetic valve is typically restricted by the upstream support portion to the same diameter as diameter d4 of opening 61. For some applications, contact between prosthetic valve 150 and upstream support portion 60 (e.g., resulting from the radially-expansive force of the valve on the support) couples the prosthetic valve to the prosthetic valve support, and/or inhibits retrograde leakage of blood therebetween.


When implanted at the native valve (e.g., when in respective expanded configurations), a height d9 of prosthetic valve 150 is typically at least 1.5 times greater (e.g., at least 3 times greater, such as at least 5 times greater) than the total height of upstream support portion 60. Typically, height d9 is at least 1.5 times greater (e.g., at least 3 times greater, such as at least 5 times greater) than depth d10 of opening 61.


As described hereinabove, upstream support portion 60 is configured to be placed against an upstream side of the native valve. It should be noted, that radial expansion of prosthetic valve 150 against inner perimeter 68 of upstream support portion 60, thereby typically does not cause the prosthetic valve support to apply a radially-expansive force to the native valve annulus. For some applications of the invention, this expansion of prosthetic valve 150 does not cause the prosthetic valve support to apply the radially-expansive force to the native valve annulus because no part of the prosthetic valve support that circumscribes the prosthetic valve is sandwiched between the prosthetic valve and the native valve annulus.


For some applications, prosthetic valve 150 is couplable to upstream support portion 60 at a plurality of positions along the length of the prosthetic valve. That is, a physician can couple the prosthetic valve at a plurality of depths within the support. For some applications, the prosthetic valve is couplable to the upstream support portion at a continuum of positions along the length of the prosthetic valve. That is, a physician can couple the prosthetic valve to the support at a continuum of depths within the support. For example, in some applications in which the prosthetic valve is configured to be coupled to the upstream support portion solely by the radially-expansive force, the prosthetic valve may be coupled to the upstream support portion at a continuum of positions along the length of the prosthetic valve.


For some applications, sealing between implant 180 and native valve 120 is facilitated by native leaflets 128 being pushed closed against the outer surface of the frame of the valve during systole, in a manner similar to that in which native valve leaflets of a healthy native valve coapt during systole.


For applications in which diameters d4 and d6 are relatively large, the proportion (e.g., the surface area) of the native leaflets that is pushed against the outer surface of the valve during systole is relatively large, thereby enhancing the sealing of the native leaflets with respect to the frame of the prosthetic valve. However, for some applications, beyond a given size, as diameters d4 and d6 increase, the native valve leaflets are pushed apart at the commissures, thereby potentially increasing a likelihood of paravalvular retrograde leakage of blood at the commissures. Therefore, for some applications of the present invention, prosthetic valve support 22 (and, typically, prosthetic valve 150) are selected such that diameters d4 and d6 are less than 90% (e.g., 5 less than 80%, e.g., less than 60%, such as less than 50%) of diameter d5 of the native valve (e.g., of the orifice of the native valve). Thus prosthetic valve support 22 facilitates sealing of the prosthetic valve with respect to the native valve, by facilitating closing of the native valve leaflets around the outer surface of the prosthetic valve.


In experiments conducted by the inventors, a prosthetic valve support 22 was implanted in two pigs. Both animals remained alive and stable (e.g., were hemodynamically stable, and had stable breathing rate and oxygen saturation) for a duration of sufficient length to withdraw delivery apparatus 140, introduce a valve-delivery system, and deploy (e.g., implant) a prosthetic valve in opening 61 of the support. The period between implanting prosthetic valve support 22 and implanting the prosthetic valve was between 5 and 10 minutes. During this duration, the native valve of the animals functioned generally normally. For example, native leaflet movement and coaptation, and blood flow therebetween was generally normal during this duration.


It is thereby hypothesized that, following implantation of prosthetic valve support 22, the heart of the subject is able to continue pumping blood sufficiently to support the subject (e.g., to maintain hemodynamic stability) for longer than a minute, e.g., longer than 2 minutes, e.g., longer than 5 minutes, such as longer than an hour. It is thereby hypothesized that a period of generally normal physiological activity of the subject of up to a minute, e.g., up to 2 minutes, e.g., up to 5 minutes, such as up to an hour, between implantation of prosthetic valve support 22 and implantation of a prosthetic valve (e.g., prosthetic valve 150) is supported by prosthetic valve support 22. It is thereby hypothesized that, for some applications, the implantation of implant 180 may be performed without the use of cardiopulmonary bypass. It is thereby further hypothesized that replacement of a native valve with implant 180, may, for some applications, be performed in a human, “off-pump,” as was performed in the pig experiments.


Reference is again made to FIG. 3I. For some applications of the invention, the prosthetic valve that is expanded within, and coupled to, prosthetic valve support 22, comprises a generally cylindrical prosthetic valve. For some applications, the prosthetic valve comprises a prior art prosthetic valve, e.g., a currently commercially-available prosthetic valve. That is, for some applications, prosthetic valve support 22 may be used to facilitate implantation of a prior art prosthetic valve, such as a currently commercially-available prosthetic valve. For some applications, and as shown in FIG. 3I, the prosthetic valve comprises prosthetic valve 150, which comprises (1) a generally cylindrical valve body 152 (e.g., a primary structural element), within which one or more prosthetic check valve elements (e.g., valve members, such as leaflets, a ball, or a disc) are disposed (not shown), and (2) one or more valve-anchoring elements 154 which protrude (e.g., radially) from the valve body. Typically, valve-anchoring elements 154 are disposed at a downstream end of prosthetic valve 150 (e.g., at a downstream end of valve body 152), and protrude outward and upstream. For some applications, and as shown in FIG. 3I, valve-anchoring elements 154 fold back toward valve body 152, and are configured to sandwich stabilizing element 80, clips 30 and/or native leaflets 128 between the valve-anchoring elements and the valve body. For some applications, prosthetic valve 150 does not comprise valve-anchoring elements 154.


As described hereinabove, coupling of prosthetic valve 150 to prosthetic valve support 22 is typically facilitated by radially-expansive force applied by the valve to the support. Typically, prosthetic valve 150 comprises an expandable lattice-structure frame 151 (e.g., comprising a plurality of struts). For applications of the invention in which upstream support portion 60 comprises inwardly-protruding barbs 67 (e.g., as shown in FIGS. 1A and 2A), the barbs protrude into frame 151 (e.g., between struts thereof), thereby further facilitating coupling of the prosthetic valve to the prosthetic valve support.


Typically, at least portions of the inner surface of prosthetic valve 150 (e.g., of valve body 152) are covered with a covering 156, to facilitate channeling of blood through the valve body, as is known in the art. That is, at least portions of prosthetic valve 150 (e.g., of valve body 152) are lined with covering 156. Covering 156 may comprise the same material(s) as covering 64 described hereinabove, and/or may comprise other materials.


For some applications, an upstream portion of prosthetic valve 150 (e.g., of valve body 152) alternatively or additionally comprises a netting 158, which facilitates coupling of the prosthetic valve to prosthetic valve support 22. Netting 158 may be disposed on the inner surface and/or the outer surface of the upstream portion of the prosthetic valve (e.g., of valve body 152), and/or between the struts of frame 151. Typically, netting 158 is disposed upstream of a point at which leaflets 182 contact (e.g., seal around) valve body 152.


Typically, netting 158 facilitates coupling of prosthetic valve 150 to prosthetic valve support 22 by providing a higher-resolution lattice through which barbs 67 of the prosthetic valve support are configured to protrude. Netting 158 may additionally insulate respective metallic surfaces of the prosthetic valve and the prosthetic valve support (e.g., of frames 62 and 151) from each other. It is hypothesized that this insulation reduces fatigue, corrosion, chipping and/or wear of the metallic surfaces, and/or electrostatic discharge between the metallic surfaces.


For some applications, a material that inhibits (e.g., prevents) tissue growth (e.g., polytetrafluoroethylene (PTFE), and/or pericardium) may be disposed on a surface of prosthetic valve 150 and/or prosthetic valve support 22 (e.g., clips 30 thereof). Alternatively or additionally, a material that facilitates (e.g., enhances) tissue growth (such as polyethylene terephthalate; PET) may be disposed on a surface of the prosthetic valve and/or the prosthetic valve support (e.g., clips 30 thereof), in order to facilitate sealing and/or coupling to the native valve.


It is hypothesized that the use of prosthetic valve support 22 advantageously facilitates delivery of a prosthetic valve via a catheter narrower than 28 Fr (i.e., less than 9.3 mm), e.g., narrower than 24 Fr (i.e., less than 8 mm), such as by allowing the use of a “minimalistic” prosthetic valve, comprising a generally cylindrical valve body, and valve members (e.g., leaflets) disposed therein, and comprising few or no other components and/or appendages. Typically, prosthetic valve support 22 is also delivered via a similarly narrow catheter, e.g., via the same catheter. The use of such a narrow catheter advantageously facilitates transluminal (e.g., transfemoral) delivery and implantation of the prosthetic valve and prosthetic valve support.


It is to be noted that, although FIGS. 3A-I show prosthetic valve support 22 being implanted and used to facilitate implantation of a prosthetic valve, the techniques described may be applied to other prosthetic valve supports described herein (e.g., prosthetic valve supports 220, 322, 422 and 522), mutatis mutandis.


Reference is made to FIGS. 4A-F, which are schematic illustrations of a system 200 for facilitating controlled expansion and/or retrievability of upstream support portion 60, in accordance with some applications of the invention. System 200 comprises one or more holding members 134, reversibly coupled to upstream support portion 60 by one or more coupling leads 202 (e.g., coupling wires). Typically, two or more (e.g., three) holding members are coupled to the upstream support portion via two or more (e.g., three) coupling leads. Typically, the ends of each coupling lead 202 are disposed within holding members 134, or more proximally (e.g., outside a body of the subject). Coupling leads 202 may comprise metallic wire, suture, or any other suitable material.


A portion (e.g., a middle portion) of each coupling lead 202 is disposed within (e.g., threaded and/or looped through) a respective portion of upstream support portion 60, thereby coupling the upstream support portion to holding members 134. Typically, this middle portion of each coupling lead is disposed through a peripheral region (e.g., close to an outer edge 69) of the prosthetic valve support.


For example, and as shown in FIG. 4A, three coupling leads 202 (e.g., coupling leads 202a, 202b, and 202c) couple three respective holding members 134 (e.g., holding members 134a, 134b and 134c) to upstream support portion 60. One end of each coupling lead 202 extends from a respective holding member 134, passes around (e.g., is looped and/or threaded through) upstream support portion 60, and returns to the same holding member. Thereby, each coupling lead is configured to apply a respective annular pulling force to the entire upstream support portion, when the coupling lead is pulled.


For some applications of the invention, system 200 is configured to facilitate transluminal retrieval of upstream support portion 60 following expansion of the upstream support portion at the native valve. Upstream support portion 60 is deployed at the native valve, e.g., as described with reference to FIGS. 3C-F, mutatis mutandis. Should it be desirable and/or necessary to retrieve upstream support portion 60 into delivery tube 130, and/or to remove the upstream support portion entirely from the subject, pulling of coupling leads 202 recompresses upstream support portion 60 into a generally cylindrical configuration, e.g., toward and/or into the compressed delivery configuration thereof (FIGS. 4B-D). Subsequently, upstream support portion 60 may be withdrawn into delivery tube 130 (FIGS. 4E-F).


System 200 may alternatively or additionally be configured to facilitate controlled expansion of upstream support portion 60. During deployment of upstream support portion 60, coupling leads 202 are gradually released (e.g., fed distally). This technique may be understood by considering FIGS. 4B-F in reverse order, mutatis mutandis. Thereby, the rate of expansion of upstream support portion 60 is controllable. Alternative configurations and/or arrangements of coupling leads 202 may be used, e.g., to facilitate controlled expansion of different portions of upstream support portion 60.


It is to be noted that the techniques described with reference to FIGS. 4A-F may be used in combination with other upstream support portions described herein (e.g., upstream support portions 90 and 100), mutatis mutandis.


Reference is made to FIG. 5, which is a schematic illustration of a step in the implantation of prosthetic valve support 22, in accordance with some applications (e.g., alternative applications) of the invention. For some applications, the step shown in FIG. 5 is performed after the implantation sequence steps shown in FIGS. 3A-3D, and prior to the steps shown in FIGS. 3F-3I, e.g., instead of or in addition to the step shown in FIG. 3E, mutatis mutandis. FIG. 5 shows prosthetic valve support subsequent to the coupling of clips 30 to leaflets 128 of the native valve, and prior to the complete release (e.g., the complete expansion) of upstream support portion 60.


For some applications of the invention, it may be desirable and/or necessary to hold clips 30 closer together than they would otherwise be disposed following complete release, and thereby expansion, of upstream support portion 60. FIG. 5 shows clips 30 being held closer together, by holding of portions of upstream support portion 60 that are in the vicinity of clips 30, closer together. At least one coupling lead (e.g., coupling wire) 210 is coupled to these portions of upstream support portion 60, and holds the portions together, as shown in FIG. 5. Coupling lead 210 may comprise metallic wire, suture, or any other suitable material.


At a later time (e.g., closer to a time at which prosthetic valve 150 is to be implanted, such as at the time at which the prosthetic valve is implanted), coupling lead 210 is released, such that the upstream support portion (and the prosthetic valve support as a whole) moves toward the configuration shown in FIGS. 3F and/or 3G.


For example, and as shown in FIG. 5, two or more coupling leads 210 may extend through a holding member 212, and loop through respective portions of upstream support portion 60. The coupling leads are decoupled from the skirt by releasing one end of each coupling lead, and unlooping the coupling lead from the upstream support portion. For some applications, holding member 212 comprises holding member 134, e.g., as described with reference to FIGS. 3C-F.


It is to be noted that the techniques described with reference to FIG. 5 may be combined with other techniques and apparatus described herein. For example, the techniques described with reference to FIG. 5 may be used for implanting other prosthetic valve supports described herein, mutatis mutandis.


Reference is made to FIGS. 6A-B, which are schematic illustrations of a prosthetic valve support 522, comprising tissue-engaging elements 24 that are couplable to each other, and decouplable from each other (e.g., reversibly coupled to each other), in accordance with some applications of the invention. Prosthetic valve support 522 typically further comprises upstream support portion 60 and/or stabilizing element 80, and the tissue-engaging elements of the prosthetic valve support typically comprise clips 30. For some applications, prosthetic valve support 522 comprises prosthetic valve support 22 (e.g., as described with reference to FIGS. 1A-D), and/or may be used in combination with techniques described herein (e.g., with reference to FIGS. 3A-I and/or 8), mutatis mutandis. For some applications, prosthetic valve support 522 does not comprise stabilizing element 80 (e.g., as described for prosthetic valve support 322 with reference to FIG. 2C, mutatis mutandis), and/or does not comprise upstream support portion 60 (e.g., as described for prosthetic valve support 422 with reference to FIG. 2D, mutatis mutandis). Similarly, the tissue-engaging elements of other prosthetic valve supports described herein may be reversibly coupled to each other as described for the tissue-engaging elements of prosthetic valve support 522, mutatis mutandis. Typically, prosthetic valve support 522 is provided with tissue-engaging elements 24 fixedly coupled to each other, and configured to be transluminally, intracorporeally decoupled from each other. Alternatively or additionally, tissue-engaging elements 24 may be configured to be extracorporeally and/or intracorporeally (e.g., transluminally) couplable to each other by a physician.



FIGS. 6A-B show prosthetic valve support 522 following implantation thereof at the native valve (e.g., as shown in FIGS. 3A-F, mutatis mutandis), and before coupling of a prosthetic valve to the prosthetic valve support (e.g., as shown in FIGS. 3H-I, mutatis mutandis), e.g., instead of or in addition to the step shown in FIG. 3G, mutatis mutandis. For some applications, FIG. 6A is thereby comparable to FIG. 3G, mutatis mutandis.



FIG. 6B shows a view from upstream of mitral valve 122 (e.g., from left atrium 124), showing the valve (e.g., leaflets 128) moving (e.g., beating) between open and closed states thereof. As is known in the art, each leaflet 128 of mitral valve 122 is generally defined as being divided into three scallops: scallops A1, A2 and A3 of the anterior leaflet, and scallops P1, P2 and P3 of the posterior leaflet. Tissue-engaging elements 24 are coupled to respective portions of leaflets 128 (e.g., scallops A2 and P2 of the anterior and posterior leaflets, respectively), and to each other, and thereby hold the portions of the leaflets to which they are coupled, close to each other (e.g., together). Portions of the leaflets that are not held close to each other (e.g., at least portions of scallops P1, P3, A1 and A3) are typically generally able to move (e.g., flap) in response to beating of the heart. Thereby, the implantation of prosthetic valve support 522 shown in FIGS. 6A-B generates two orifices 530, each orifice defined by (e.g., surrounded by) a respective portion of each leaflet, and thereby, in effect, functioning as a respective check valve. For example, the native valve may function as two (e.g., parallel) check valves. For some applications of the invention, the resulting arrangement of leaflets 128 resembles the “double-orifice” arrangement of leaflets of a valve that has been repaired using the Alfieri stitch, as is known in the mitral valve repair art. Thereby, prosthetic valve support 522 is configured to be coupled to the native heart valve (e.g., to leaflets thereof) without eliminating check valve functionality of the native heart valve, by coupling together respective portions of the two leaflets, such that (1) the native leaflets define two orifices, and (2) the native valve functions as two (e.g., parallel) check valves (e.g., in a manner that is modified with respect to the natural function of the native valve).


Subsequently (e.g., immediately subsequently, or after more than a minute, e.g., after more than 2 minutes, e.g., after more than 5 minutes, such as after more than an hour), a prosthetic valve is transluminally delivered, and implanted at the native valve by coupling the prosthetic valve to prosthetic valve support 522 (e.g., as described with reference to FIGS. 3H-I, mutatis mutandis). Prior to (e.g., immediately prior to) implantation of the prosthetic valve, tissue-engaging elements 24 are decoupled from each other, such that the tissue-engaging elements (and thereby leaflets 128) are movable away from each other, and such that the prosthetic valve may be disposed therebetween during coupling of the prosthetic valve to the prosthetic valve support. For some applications of the invention, between (1) the decoupling of the tissue-engaging elements from each other, and (2) the coupling of the prosthetic valve to the prosthetic valve support, the prosthetic valve support allows (1) the native valve (e.g., the leaflets thereof) to define a single orifice, and (2) the native valve to function as a single check valve (e.g., as described with reference to FIG. 3G, mutatis mutandis).


For some applications of the invention, tissue-engaging elements 24 are coupled to each other by a locking element (e.g., a locking wire), and the locking element is unlocked (e.g., the locking wire is cut or otherwise decoupled), prior to implantation of the prosthetic valve support. For some applications of the invention, tissue-engaging elements 24 are coupled to each other by a coupling lead that which is held in place, and removed, decoupled, and/or loosened immediately prior to implantation of the prosthetic valve. For example, the coupling lead may extend through a holding member and be looped through and/or around the tissue-engaging elements. For some such applications, the holding member may comprise holding member 212, and the coupling lead may comprise coupling lead 210 (e.g., described with reference to FIG. 5, mutatis mutandis), the coupling lead being coupled to tissue-engaging elements 24, rather than to portions of the upstream support portion. For some applications of the invention, prosthetic valve support 522 is configured such that the tissue-engaging elements are decoupled (e.g., automatically) when the prosthetic valve is implanted at the native valve (e.g., when the prosthetic valve is expanded within the prosthetic valve support).


It is hypothesized that, following implantation of prosthetic valve support 522, the heart of the subject is able to continue pumping blood sufficiently to support the subject and/or to maintain hemodynamic stability for longer than a minute, e.g., longer than 2 minutes, e.g., longer than 5 minutes, such as longer than an hour. It is thereby hypothesized that a period of generally normal physiological activity of the subject of up to a minute (e.g., up to 2 minutes, e.g., up to 5 minutes, such as up to an hour) between implantation of prosthetic valve support 522 and implantation of a prosthetic valve, is supported by prosthetic valve support 522. It is thereby hypothesized that the implantation of an implant comprising prosthetic valve support 522 and a prosthetic valve, may be performed without the use of cardiopulmonary bypass. It is thereby hypothesized that replacement of a native valve with such an implant may be performed in a human, “off-pump.”


It is to be noted that the techniques described with reference to FIGS. 6A-B may be combined with other techniques and apparatus described herein. For example, tissue-engaging elements (e.g., clips) of other prosthetic valve supports described herein may be reversibly coupled to each other, so as to achieve the double-orifice configuration of the native valve described with reference to FIGS. 6A-B, mutatis mutandis.


Reference is made to FIG. 7, which is a schematic illustration of a prosthetic valve support 220, comprising upstream support portion 60 and three clips 30 (or other tissue-engaging elements 24), in accordance with some applications of the invention. Clips 30 are typically coupled to upstream support portion 60 via connectors 70, as described hereinabove, mutatis mutandis. For some applications, and as shown in FIG. 7, prosthetic valve support 220 is configured to be coupled to mitral valve 122 of the subject. One clip 30 is configured to be coupled to anterior leaflet 128a of the mitral valve (e.g., to the A2 scallop thereof), and two clips are configured to be coupled to posterior leaflet 128b (e.g., to the P1 and P3 scallops thereof, respectively). For some applications, prosthetic valve support 220 is configured to be coupled to a native tricuspid valve of the subject, and each clip 30 is configured to be coupled to a respective leaflet of the tricuspid valve.


It is to be noted that the techniques described with reference to FIG. 7 may be combined with other techniques and apparatus described herein. For example, other prosthetic valve supports described herein (e.g., prosthetic valve supports 220, 322, 422 and 522) may comprise three tissue-engaging elements, mutatis mutandis.


Reference is made to FIG. 8, which is a schematic illustration of implantation, in heart 250 of the subject, of a prosthetic valve 240, facilitated by prosthetic valve support 22, in accordance with some applications of the invention. For some applications, prosthetic valve 240 comprises and/or has features of prosthetic valve 150, described hereinabove. For some applications, and as shown in FIG. 3H, both the prosthetic valve support and the prosthetic valve are configured to be delivered from the upstream side of mitral valve 122, e.g., transfemorally and/or transseptally. For some applications of the invention, the prosthetic valve is configured to be delivered via a retrograde approach. For example, and as shown in FIG. 8, following implantation of prosthetic valve support 22 at mitral valve 122, prosthetic valve 240 is delivered via left ventricle 126, e.g., via aorta 252 such as via the femoral artery of the subject. Alternatively, prosthetic valve 240 may be delivered transapically. For applications in which the prosthetic valve is delivered via a retrograde approach, prosthetic valve support 22 is typically delivered as described hereinabove, but may alternatively be delivered via a retrograde approach.


It is to be noted that the techniques described with reference to FIG. 8 may be combined with other techniques and apparatus described herein. For example, the techniques described with reference to FIG. 8 may be used for implanting other prosthetic valves described herein, and/or for delivering a prosthetic valve to other prosthetic valve supports described herein, mutatis mutandis.


Reference is made to FIGS. 9A-C, which are schematic illustrations of prosthetic valve supports, each comprising upstream support portion 60, coupled to tissue-engaging elements 24 (comprising clips 30) via one or more variable-length connectors 260, in accordance with respective applications of the invention. Variable-length connectors 260 are typically positioned in the same or similar way as connectors 70, and typically perform the same or similar functions as connectors 70, described hereinabove.



FIG. 9A shows a prosthetic valve support 270, comprising variable-length connectors 260, embodied as adjustable-length connectors 272, in accordance with some applications of the invention. Connectors 272 comprise a holding wire 274, which is slidably coupled to upstream support portion 60, is fixedly coupled to tissue-engaging elements 24, and defines a rack 276, comprising a plurality of teeth 277, disposed along at least part of the length of the holding wire. The distance between upstream support portion 60 (e.g., inner perimeter 68 thereof) and each tissue-engaging element 24 is adjustable by adjusting the length of the respective holding wire 274 that is disposed between the upstream support portion and the tissue-engaging element. Typically, this length is adjusted by pulling the holding wire proximally. Thereby, the length of connectors 272 is variable, by the connectors being adjustable.


An engaging element 278 (e.g., a pawl, a ridge, or a tooth), typically within a ratchet housing 280, allows the length of holding wire 274 between the upstream support portion and the clip to be shortened, but not to be lengthened. Thereby, holding wire 274 (e.g., rack 276 thereof) and ratchet housing 280 (e.g., engaging element 278 thereof) act as a ratchet. For some applications, and as shown in FIG. 9A, ratchet housing 280 is movable with respect to upstream support portion 60, and is slid distally over holding wire 274, such as by a pusher 282 (e.g., a controller tube). Alternatively, ratchet housing 280 is fixedly coupled to upstream support portion 60, e.g., such that the length of holding wire 274 is adjusted by pulling the holding wire proximally. Typically, but not necessarily, the length of holding wire 274 (and thereby of connectors 272) is adjusted subsequent to coupling of clips 30 to the native leaflets, and further typically, also subsequent to deployment of upstream support portion 60.



FIG. 9B shows a prosthetic valve support 290, comprising variable-length connectors 260, embodied as elastic connectors 292 (e.g., stretchable connectors), in accordance with some applications of the invention. Connectors 292 comprise one or more (e.g., two) elastic elements 294, such as tension springs (e.g., coil tension springs). The distance between upstream support portion 60 (e.g., inner perimeter 68 thereof) and each clip is variable due to stretching and contracting of elastic elements 294. Thereby, the length of connectors 292 is variable, by the connectors being elastic.


The length, elasticity and/or force constant of elastic elements 294 may be adapted to the native valve to which prosthetic valve support 290 is coupled, and/or to the individual subject (e.g., pre-selected according to the native valve and/or the individual subject). For example, elastic elements that have a relatively low force constant may allow leaflets of the native valve to move more freely, and elastic elements that have a relatively high force constant may couple the prosthetic valve support to the native valve more fixedly. Alternatively or additionally, connectors 260 may be configured to stretch and contract with movement (e.g., flapping) of the leaflets of the native valve, may thereby allow the leaflets to move more freely compared to some inelastic connectors, and may thereby facilitate the coupling of the prosthetic valve support to the native valve without eliminating check valve functionality of the native valve.



FIG. 9C shows a prosthetic valve support 300, comprising variable-length connectors 260, embodied as elastic connectors 302, in accordance with some applications of the invention. Connectors 302 comprise an elastic element 304, such as a tension spring (e.g., a coil tension spring). For some applications, elastic element 304 comprises elastic element 294, described with reference to FIG. 9B. Connectors 302 further comprise a restrictor 306, which restricts elasticity of element 304. Typically, restrictor 306 holds elastic element 304 in an expanded (e.g., stretched) state. Typically, restrictor 306 is releasable (e.g., decouplable) from elastic element 304, so as to allow the elastic element to contract.


For some applications, restrictor 306 may be mechanically releasable (e.g., removable) by the user. For some applications, and as shown in FIG. 9C, restrictor 306 may comprise a material that disintegrates in the body (e.g., a material that is at least in part soluble and/or biodegradable and/or biosorbent). For such applications, restrictor 306 typically disintegrates over a predictable period of time e.g., between 15 minutes and 1 week, such as between 30 minutes and 3 days, for example, between 1 hour and 1 day. For some applications, restrictor 306 is configured to decouple from (i.e., release) elastic element 304 gradually, e.g., in stages. For some applications, restrictor 306 is coupled to elastic element 304 and/or another part of prosthetic valve support 300, such that, following the release of the elastic element, the restrictor is retained, so as not to enter the vasculature of the subject.


For some applications of the invention, prosthetic valve support 300 and connectors 302 are used in instances in which it is desirable to have a first period during which the connectors are longer (e.g., prior to implantation of a prosthetic valve), and a second period during which the connectors are shorter (e.g., subsequent to implantation of the prosthetic valve).


Reference is again made to FIGS. 9A-C. It should be noted that throughout this patent application, including in the claims, the term “variable”, with respect to the length of the connectors that couple tissue-engaging elements 24 (e.g., clips 30) to upstream support portion 60, includes (1) length variability due to intervention, such as a physician adjusting the length (e.g., as described for adjustable-length connectors 272), and (2) length variability due to elasticity and/or another configuration that facilitates the connector changing length, such as without intervention (e.g., as described for elastic connectors 292 and 302). It is hypothesized that, for some applications, connector length variability (1) facilitates reduction of valve regurgitation prior to implantation of the prosthetic valve (2) provides adjustability for anatomical differences (e.g., leaflet size) between subjects, and/or (3) increases stability of the prosthetic valve, e.g., by reducing axial rotation of the prosthetic valve, such as by the connector length being shortened after implantation of the prosthetic valve.


It is to be noted that the apparatus and techniques described with reference to FIGS. 9A-C may be combined with other techniques and apparatus described herein. For example, any of the prosthetic valve supports may comprise variable-length connectors 260 (e.g., adjustable-length connectors 272, elastic connectors 292, and/or elastic connectors 302), mutatis mutandis. Similarly, connector length adjustment may be used in combination with the implantation techniques described with reference to FIGS. 3A-I and/or 8, mutatis mutandis.


Reference is again made to FIGS. 1A-9C. For some applications of the invention, one or more of the elements, portions and/or components described hereinabove comprise radiopaque markers so as to facilitate implantation thereof (e.g., by using imaging techniques such as fluoroscopy). For example, tissue-engaging elements 24 (e.g., clips 30) and/or stabilizing element 80 may comprise radiopaque markers, e.g., so as to facilitate positioning (e.g., orientation) of the prosthetic valve support with respect to the native valve. Alternatively or additionally, inner perimeter 68 of upstream support portion 60 and/or stabilizing element 80 may comprise radiopaque markers, e.g., so as to indicate the opening(s) in which the prosthetic valve is to be implanted. Alternatively or additionally, the prosthetic valve may comprise radiopaque markers to facilitate positioning thereof with respect to the prosthetic valve support.


Reference is again made to FIGS. 1A-9C. For some applications of the invention, the tissue-engaging elements of the prosthetic valve supports described hereinabove are movable with respect to each other at at least some time subsequent to the coupling of the tissue-engaging elements being coupled to the leaflets of the native valve. For example, tissue-engaging elements 24 (e.g., clips 30) of prosthetic valve support 22 are movable with respect to each other, e.g., as shown in FIG. 3G. Similarly, tissue-engaging elements 24 (e.g., clips 30) of prosthetic valve support 522 are movable with respect to each other once they have been decoupled from each other.


Reference is again made to FIGS. 1A-9C. The prosthetic valve supports described hereinabove are typically configured to be coupled to the leaflets of the native valve without eliminating check-valve functionality of the native valve. That is, although the coupling of the prosthetic valve support to the native valve may alter the position and/or movement of the native leaflets, the native valve still facilitates at least some net one-way movement of blood therethrough (e.g., as described with reference to FIGS. 3G and 6A-B). For some such instances, the altered position and/or movement of the native leaflets may, in fact, enhance check valve functionality of the native valve, thereby substantially “repairing” the native valve. For some such instances, a physician may choose not to implant a prosthetic valve during the same procedure as the implantation of the prosthetic valve support, but instead may choose to allow the subject to return to activities of daily living, whilst retaining the option to implant a prosthetic valve at a later date. That is, for some applications of the invention, the prosthetic valve support is configured to be implanted without a prosthetic valve, and to provide (1) repair of the native valve, and (2) an implantation site that is pre-prepared for subsequent implantation of a prosthetic valve at a later date, should such implantation be subsequently considered necessary.


It is to be noted that, although some techniques described hereinabove are generally illustrated as being used at the mitral valve of the subject, the scope of the invention includes implanting a prosthetic valve support and prosthetic valve (e.g., those described hereinabove) at other native heart valves of the subject, such as at the tricuspid valve, the aortic valve, or the pulmonary valve of the subject, mutatis mutandis.


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. Apparatus for use with a valve of a heart of a subject, the apparatus comprising: a delivery tool, transluminally advanceable to the heart, and comprising a clip controller; andan implant, having a central longitudinal axis, and coupled to a distal portion of the delivery tool, and comprising: a clip: disposed laterally from the longitudinal axis,comprising a first arm, and a second arm articulatably coupled to the first arm, andconfigured to be attached to a leaflet of the valve by sandwiching the leaflet between the first arm and the second arm by articulation between the first arm and the second arm, such that the second arm is disposed laterally from the first arm; anda clip-controller interface, reversibly coupled to the clip controller, and comprising: a first interface portion, configured to be slid linearly by the clip controller, anda second interface portion, articulatably coupled to the first interface portion, and articulatably coupled to the second arm, such that linear sliding of the first interface portion causes the second interface portion to (i) articulate with respect to the first interface portion, and (ii) push the second arm to articulate toward the central longitudinal axis.
  • 2. The apparatus according to claim 1, wherein: the clip is a first clip, the leaflet is a first leaflet of the valve, and the first clip is configured to be attached to a middle scallop of the first leaflet; andthe implant further comprises a second clip, disposed on an opposite lateral side of the longitudinal axis from the first clip, and configured to be attached to a middle scallop of a second leaflet of the valve such that, while the first clip is attached to the middle scallop of the first leaflet and the second clip is attached to the middle scallop of the second leaflet, the implant arranges the first leaflet and the second leaflet into a double-orifice configuration.
  • 3. The apparatus according to claim 2, wherein the first clip and the second clip are controllable independently of each other.
  • 4. The apparatus according to claim 1, wherein the first arm comprises teeth, configured to pierce the leaflet.
  • 5. The apparatus according to claim 4, wherein the clip comprises padding, configured to cushion contact between the clip and the leaflet.
  • 6. The apparatus according to claim 1, wherein the second interface portion is articulatably coupled to the second arm at a lateral surface of the second arm.
  • 7. The apparatus according to claim 1, wherein the implant comprises a locking element, configured to facilitate locking of the clip subsequent to closing of the clip.
  • 8. The apparatus according to claim 1, wherein the second arm is articulatable by 60-180 degrees with respect to the first arm.
  • 9. The apparatus according to claim 1, wherein the second arm is articulatable by 80-180 degrees with respect to the first arm.
  • 10. The apparatus according to claim 1, wherein the second arm is articulatable by 100-180 degrees with respect to the first arm.
  • 11. The apparatus according to claim 1, wherein the second arm is articulatable by 120-180 degrees with respect to the first arm.
CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a Continuation of U.S. application Ser. No. 16/284,331 to HaCohen, filed Feb. 25, 2019, which published as US 2019/0183644, and which is a Continuation of U.S. application Ser. No. 15/197,069 to Gross et al., filed Jun. 29, 2016, which published as US 2016/0310274 (now U.S. Pat. No. 10,226,341), and which is a Continuation of U.S. application Ser. No. 14/237,258 to Gross et al., which published as US 2014/0257475 (now U.S. Pat. No. 9,387,078), and which is the US National Phase of PCT Patent Application IL2012/000293 to Gross et al., filed Aug. 5, 2012, which published as WO 2013/021375, and which: (1) claims priority from: U.S. 61/515,372 to Gross et al., filed Aug. 5, 2011;U.S. 61/525,281 to Gross et al., filed Aug. 19, 2011;U.S. 61/537,276 to Gross et al., filed Sep. 21, 2011;U.S. 61/555,160 to Gross et al., filed Nov. 3, 2011;U.S. 61/588,892 to Gross et al., filed Jan. 20, 2012; andU.S. application Ser. No. 13/412,814 to Gross et al., filed Mar. 6, 2012, which published as US 2013/0035759 (now U.S. Pat. No. 8,852,272), all of which are incorporated herein by reference; and(2) is a continuation-in-part of U.S. application Ser. No. 13/412,814 to Gross et al., filed Mar. 6, 2012, which published as US 2013/0035759 (now U.S. Pat. No. 8,852,272).

US Referenced Citations (1074)
Number Name Date Kind
3874388 King et al. Apr 1975 A
4222126 Boretos et al. Sep 1980 A
4261342 Aranguren Apr 1981 A
4340091 Skelton et al. Jul 1982 A
4423525 Vallana et al. Jan 1984 A
4853986 Allen Aug 1989 A
4892541 Alonso Jan 1990 A
4972494 White et al. Nov 1990 A
5108420 Marks Apr 1992 A
5201757 Heyn et al. Apr 1993 A
5314473 Godin May 1994 A
5405378 Strecker Apr 1995 A
5443500 Sigwart Aug 1995 A
5607444 Lam Mar 1997 A
5607470 Milo Mar 1997 A
5647857 Anderson et al. Jul 1997 A
5713948 Uflacker Feb 1998 A
5716417 Girard et al. Feb 1998 A
5741297 Simon Apr 1998 A
5765682 Bley et al. Jun 1998 A
5776140 Cottone Jul 1998 A
5868777 Lam Feb 1999 A
5873906 Lau et al. Feb 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5980565 Jayaraman Nov 1999 A
6010530 Goicoechea Jan 2000 A
6019787 Richard et al. Feb 2000 A
6042607 Williamson, IV Mar 2000 A
6074417 Peredo Jun 2000 A
6113612 Swanson et al. Sep 2000 A
6120534 Ruiz Sep 2000 A
6126686 Badylak et al. Oct 2000 A
6152937 Peterson et al. Nov 2000 A
6165183 Kuehn et al. Dec 2000 A
6165210 Lau et al. Dec 2000 A
6187020 Zegdi et al. Feb 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6254609 Vrba et al. Jul 2001 B1
6264700 Kilcoyne et al. Jul 2001 B1
6287339 Vasquez et al. Sep 2001 B1
6312465 Griffin et al. Nov 2001 B1
6332893 Mortier et al. Dec 2001 B1
6334873 Lane et al. Jan 2002 B1
6346074 Roth Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6352561 Leopold et al. Mar 2002 B1
6391036 Berg et al. May 2002 B1
6402780 Williamson, IV Jun 2002 B2
6409755 Vrba Jun 2002 B1
6419696 Ortiz et al. Jul 2002 B1
6428550 Vargas et al. Aug 2002 B1
6440164 Dimatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6511491 Grudem et al. Jan 2003 B2
6530952 Vesely Mar 2003 B2
6540782 Snyders Apr 2003 B1
6551350 Thornton et al. Apr 2003 B1
6558396 Inoue May 2003 B1
6558418 Carpentier et al. May 2003 B2
6569196 Vesely May 2003 B1
6602263 Swanson et al. Aug 2003 B1
6616675 Evard et al. Sep 2003 B1
6652556 VanTassel et al. Nov 2003 B1
6669724 Park et al. Dec 2003 B2
6682558 Tu et al. Jan 2004 B2
6699256 Logan et al. Mar 2004 B1
6716244 Klaco Apr 2004 B2
6719781 Kim Apr 2004 B1
6730118 Spenser et al. May 2004 B2
6730121 Ortiz et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6764518 Godin Jul 2004 B2
6767362 Schreck Jul 2004 B2
6797002 Spence et al. Sep 2004 B2
6821297 Snyders Nov 2004 B2
6830585 Artof et al. Dec 2004 B1
6830638 Boylan et al. Dec 2004 B2
6893460 Spenser et al. May 2005 B2
6926715 Hauck et al. Aug 2005 B1
6951571 Srivastava Oct 2005 B1
6960217 Bolduc Nov 2005 B2
6964684 Ortiz et al. Nov 2005 B2
6974476 McGuckin et al. Dec 2005 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7041132 Quijano et al. May 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7077861 Spence Jul 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7101396 Artof et al. Sep 2006 B2
7137184 Schreck Nov 2006 B2
7172625 Shu et al. Feb 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal Apr 2007 B2
7226467 Lucatero et al. Jun 2007 B2
7226477 Cox Jun 2007 B2
7261686 Couvillon, Jr. Aug 2007 B2
7288097 Séguin Oct 2007 B2
7288111 Holloway et al. Oct 2007 B1
7316716 Egan Jan 2008 B2
7329279 Haug et al. Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7351256 Hojeibane et al. Apr 2008 B2
7374573 Gabbay May 2008 B2
7377938 Sarac et al. May 2008 B2
7381218 Schreck Jun 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7404824 Webler et al. Jul 2008 B1
7422603 Lane Sep 2008 B2
7429269 Schwammenthal Sep 2008 B2
7442204 Schwammenthal Oct 2008 B2
7445630 Lashinski et al. Nov 2008 B2
7455677 Vargas et al. Nov 2008 B2
7455688 Furst et al. Nov 2008 B2
7462162 Phan et al. Dec 2008 B2
7481838 Carpentier et al. Jan 2009 B2
7510575 Spenser et al. Mar 2009 B2
7513909 Lane et al. Apr 2009 B2
7524331 Birdsall Apr 2009 B2
7527646 Rahdert et al. May 2009 B2
7556632 Zadno Jul 2009 B2
7556646 Yang et al. Jul 2009 B2
7563267 Goldfarb et al. Jul 2009 B2
7563273 Goldfarb et al. Jul 2009 B2
7582111 Krolik et al. Sep 2009 B2
7585321 Cribier Sep 2009 B2
7597711 Drews et al. Oct 2009 B2
7608091 Goldfarb et al. Oct 2009 B2
7611534 Kapadia et al. Nov 2009 B2
7621948 Hermann et al. Nov 2009 B2
7625403 Krivoruchko Dec 2009 B2
7632302 Vreeman et al. Dec 2009 B2
7635329 Goldfarb et al. Dec 2009 B2
7648528 Styrc Jan 2010 B2
7655015 Goldfarb et al. Feb 2010 B2
7666204 Thornton et al. Feb 2010 B2
7682380 Thornton et al. Mar 2010 B2
7708775 Rowe et al. May 2010 B2
7717952 Case et al. May 2010 B2
7717955 Lane et al. May 2010 B2
7731741 Eidenschink Jun 2010 B2
7736388 Goldfarb et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7753922 Starksen Jul 2010 B2
7753949 Lamphere et al. Jul 2010 B2
7758595 Allen et al. Jul 2010 B2
7758632 Hojeibane et al. Jul 2010 B2
7758640 Vesely Jul 2010 B2
7771467 Svensson Aug 2010 B2
7771469 Liddicoat Aug 2010 B2
7776083 Vesely Aug 2010 B2
7780726 Seguin Aug 2010 B2
7799069 Bailey et al. Sep 2010 B2
7803181 Furst et al. Sep 2010 B2
7811296 Goldfarb et al. Oct 2010 B2
7811316 Kalmann et al. Oct 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7837645 Bessler et al. Nov 2010 B2
7837727 Goetz et al. Nov 2010 B2
7842081 Yadin Nov 2010 B2
7850725 Vardi et al. Dec 2010 B2
7871432 Bergin Jan 2011 B2
7871436 Ryan et al. Jan 2011 B2
7887583 Macoviak Feb 2011 B2
7892281 Seguin et al. Feb 2011 B2
7896915 Guyenot et al. Mar 2011 B2
7914544 Nguyen et al. Mar 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7927370 Webler et al. Apr 2011 B2
7942927 Kaye et al. May 2011 B2
7947072 Yang et al. May 2011 B2
7947075 Goetz et al. May 2011 B2
7951195 Antonsson et al. May 2011 B2
7955375 Agnew Jun 2011 B2
7955377 Melsheimer Jun 2011 B2
7955384 Rafiee et al. Jun 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7967833 Sterman et al. Jun 2011 B2
7967857 Lane Jun 2011 B2
7981151 Rowe Jul 2011 B2
7981153 Fogarty et al. Jul 2011 B2
7992567 Hirotsuka et al. Aug 2011 B2
7993393 Carpentier et al. Aug 2011 B2
8002825 Letac et al. Aug 2011 B2
8002826 Seguin Aug 2011 B2
8016877 Seguin et al. Sep 2011 B2
8016882 Macoviak Sep 2011 B2
8021420 Dolan Sep 2011 B2
8021421 Fogarty et al. Sep 2011 B2
8025695 Fogarty et al. Sep 2011 B2
8029518 Goldfarb et al. Oct 2011 B2
8029557 Sobrino-Serrano et al. Oct 2011 B2
8029564 Johnson et al. Oct 2011 B2
8034104 Carpentier et al. Oct 2011 B2
8038720 Wallace et al. Oct 2011 B2
8043360 McNamara et al. Oct 2011 B2
8048138 Sulivan et al. Nov 2011 B2
8048140 Purdy Nov 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052592 Goldfarb et al. Nov 2011 B2
8052741 Bruszewski et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8057493 Goldfarb et al. Nov 2011 B2
8057532 Hoffman Nov 2011 B2
8057540 Letac et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8070708 Rottenberg et al. Dec 2011 B2
8070800 Lock et al. Dec 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8070804 Hyde Dec 2011 B2
8075611 Milwee et al. Dec 2011 B2
8080054 Rowe Dec 2011 B2
8083793 Lane et al. Dec 2011 B2
D652927 Braido et al. Jan 2012 S
D653341 Braido et al. Jan 2012 S
8092518 Schreck Jan 2012 B2
8092520 Quadri Jan 2012 B2
8092521 Figulla et al. Jan 2012 B2
8105377 Liddicoat Jan 2012 B2
8109996 Stacchino et al. Feb 2012 B2
8118866 Herrmann et al. Feb 2012 B2
8133270 Kheradvar et al. Mar 2012 B2
8136218 Millwee et al. Mar 2012 B2
8137398 Tuval et al. Mar 2012 B2
8142492 Forster et al. Mar 2012 B2
8142494 Rahdert et al. Mar 2012 B2
8142496 Berreklouw Mar 2012 B2
8142497 Friedman Mar 2012 B2
8147504 Ino et al. Apr 2012 B2
8157852 Bloom et al. Apr 2012 B2
8157853 Laske et al. Apr 2012 B2
8157860 McNamara et al. Apr 2012 B2
8163008 Wilson et al. Apr 2012 B2
8163014 Lane et al. Apr 2012 B2
D660433 Braido et al. May 2012 S
D660967 Braido et al. May 2012 S
8167894 Miles et al. May 2012 B2
8167932 Bourang et al. May 2012 B2
8167935 McGuckin, Jr. et al. May 2012 B2
8172896 McNamara et al. May 2012 B2
8172898 Alferness et al. May 2012 B2
8177836 Lee et al. May 2012 B2
8182528 Salahieh et al. May 2012 B2
8211169 Lane et al. Jul 2012 B2
8216256 Raschdorf, Jr. et al. Jul 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8221492 Case et al. Jul 2012 B2
8221493 Boyle et al. Jul 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8231670 Salahieh et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8236049 Rowe et al. Aug 2012 B2
8252042 McNamara et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8257390 Carley et al. Sep 2012 B2
8267988 Hamer et al. Sep 2012 B2
8277501 Chalekian et al. Oct 2012 B2
8287591 Keidar et al. Oct 2012 B2
8298280 Yadin et al. Oct 2012 B2
8303653 Bonhoeffer et al. Nov 2012 B2
8308798 Pintor et al. Nov 2012 B2
8317853 Agnew Nov 2012 B2
8317855 Gregorich et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8337541 Quadri et al. Dec 2012 B2
8343174 Goldfarb et al. Jan 2013 B2
8343213 Salahieh et al. Jan 2013 B2
8348999 Kheradvar et al. Jan 2013 B2
8366767 Zhang Feb 2013 B2
8372140 Hoffman et al. Feb 2013 B2
8377119 Drews et al. Feb 2013 B2
8398708 Meiri et al. Mar 2013 B2
8403981 Forster et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8408214 Spenser Apr 2013 B2
8414644 Quadri et al. Apr 2013 B2
8425593 Braido et al. Apr 2013 B2
8430934 Das Apr 2013 B2
8444689 Zhang May 2013 B2
8449599 Chau et al. May 2013 B2
8449625 Campbell et al. May 2013 B2
8454686 Alkhatib Jun 2013 B2
8460365 Haverkost et al. Jun 2013 B2
8474460 Barrett et al. Jul 2013 B2
8512400 Tran et al. Aug 2013 B2
8539662 Stacchino et al. Sep 2013 B2
8545544 Spenser et al. Oct 2013 B2
8551160 Figulla et al. Oct 2013 B2
8551161 Dolan Oct 2013 B2
8562672 Bonhoeffer et al. Oct 2013 B2
8568475 Nguyen et al. Oct 2013 B2
8579964 Lane et al. Nov 2013 B2
8579965 Bonhoeffer et al. Nov 2013 B2
8585755 Chau et al. Nov 2013 B2
8585756 Bonhoeffer et al. Nov 2013 B2
8591460 Wilson et al. Nov 2013 B2
8591570 Revuelta et al. Nov 2013 B2
8623075 Murray et al. Jan 2014 B2
8623080 Fogarty et al. Jan 2014 B2
8628569 Benichou et al. Jan 2014 B2
8628570 Seguin Jan 2014 B2
8628571 Hacohen et al. Jan 2014 B1
8652203 Quadri et al. Feb 2014 B2
8652204 Quill et al. Feb 2014 B2
8657872 Seguin Feb 2014 B2
8663322 Keranen Mar 2014 B2
8673020 Sobrino-Serrano et al. Mar 2014 B2
8679174 Ottma et al. Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8696742 Pintor et al. Apr 2014 B2
8728155 Montorfano et al. May 2014 B2
8734507 Keranen May 2014 B2
8747460 Tuval et al. Jun 2014 B2
8771345 Tuval et al. Jul 2014 B2
8784472 Eidenschink Jul 2014 B2
8784479 Antonsson et al. Jul 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8795355 Alkhatib Aug 2014 B2
8795356 Quadri et al. Aug 2014 B2
8795357 Yohanan et al. Aug 2014 B2
8801776 House et al. Aug 2014 B2
8808366 Braido et al. Aug 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8840664 Karapetian et al. Sep 2014 B2
8845722 Gabbay Sep 2014 B2
8852261 White Oct 2014 B2
8852272 Gross Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8870949 Rowe Oct 2014 B2
8870950 Hacohen Oct 2014 B2
8876800 Behan Nov 2014 B2
8894702 Quadri et al. Nov 2014 B2
8900294 Paniagua et al. Dec 2014 B2
8900295 Migliazza et al. Dec 2014 B2
8906083 Obermiller et al. Dec 2014 B2
8911455 Quadri et al. Dec 2014 B2
8911489 Ben-Muvhar Dec 2014 B2
8911493 Rowe et al. Dec 2014 B2
8932343 Alkhatib et al. Jan 2015 B2
8961595 Alkhatib Feb 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986370 Annest Mar 2015 B2
8986373 Chau et al. Mar 2015 B2
8986375 Garde et al. Mar 2015 B2
8992599 Thubrikar et al. Mar 2015 B2
8992604 Gross Mar 2015 B2
8998982 Richter Apr 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011468 Ketai et al. Apr 2015 B2
9011527 Li et al. Apr 2015 B2
9017399 Gross Apr 2015 B2
D730520 Braido et al. May 2015 S
D730521 Braido et al. May 2015 S
9023100 Quadri May 2015 B2
9034032 McLean et al. May 2015 B2
9034033 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
D732666 Nguyen et al. Jun 2015 S
9050188 Schweich et al. Jun 2015 B2
9060858 Thornton et al. Jun 2015 B2
9072603 Tuval et al. Jul 2015 B2
9084676 Chau et al. Jul 2015 B2
9095434 Rowe Aug 2015 B2
9119719 Zipory Sep 2015 B2
9125738 Figulla et al. Sep 2015 B2
9125740 Morriss et al. Sep 2015 B2
9132006 Spenser et al. Sep 2015 B2
9132009 Hacohen Sep 2015 B2
9138312 Tuval et al. Sep 2015 B2
9155619 Liu et al. Oct 2015 B2
9173659 Bodewadt et al. Nov 2015 B2
9173738 Murray et al. Nov 2015 B2
9220594 Braido et al. Dec 2015 B2
9226820 Braido et al. Jan 2016 B2
9226839 Kariniemi et al. Jan 2016 B1
9232995 Kovalsky et al. Jan 2016 B2
9241790 Lane et al. Jan 2016 B2
9241791 Braido et al. Jan 2016 B2
9241794 Braido et al. Jan 2016 B2
9248014 Lane et al. Feb 2016 B2
9277994 Miller Mar 2016 B2
9289290 Alkhatib et al. Mar 2016 B2
9289291 Gorman et al. Mar 2016 B2
9295550 Nguyen et al. Mar 2016 B2
9295551 Straubinger et al. Mar 2016 B2
9295552 McLean et al. Mar 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9320591 Bolduc Apr 2016 B2
D755384 Pesce et al. May 2016 S
9326852 Spenser May 2016 B2
9326876 Acosta et al. May 2016 B2
9345573 Nyuli et al. May 2016 B2
9387078 Gross Jul 2016 B2
9393110 Levi et al. Jul 2016 B2
9421098 Gifford et al. Aug 2016 B2
9427303 Liddy et al. Aug 2016 B2
9427316 Schweich, Jr. et al. Aug 2016 B2
9439757 Wallace et al. Sep 2016 B2
9463102 Kelly Oct 2016 B2
9474599 Keranen Oct 2016 B2
9474638 Robinson et al. Oct 2016 B2
9480559 Vidlund et al. Nov 2016 B2
9492273 Wallace et al. Nov 2016 B2
9498314 Behan Nov 2016 B2
9532870 Cooper et al. Jan 2017 B2
9554897 Lane et al. Jan 2017 B2
9554899 Granada et al. Jan 2017 B2
9561103 Granada et al. Feb 2017 B2
9566152 Schweich et al. Feb 2017 B2
9597182 Straubinger et al. Mar 2017 B2
9629716 Seguin Apr 2017 B2
9681952 Hacohen et al. Jun 2017 B2
9717591 Chau et al. Aug 2017 B2
9743932 Amplatz et al. Aug 2017 B2
9763657 Hacohen Sep 2017 B2
9763817 Roeder Sep 2017 B2
9770256 Cohen et al. Sep 2017 B2
9788941 Hacohen Oct 2017 B2
9895226 Harari et al. Feb 2018 B1
9987132 Hariton et al. Jun 2018 B1
10076415 Metchik et al. Sep 2018 B1
10105222 Metchik et al. Oct 2018 B1
10111751 Metchik et al. Oct 2018 B1
10123873 Metchik et al. Nov 2018 B1
10130475 Metchik et al. Nov 2018 B1
10136993 Metchik et al. Nov 2018 B1
10143552 Wallace et al. Dec 2018 B2
10149761 Granada et al. Dec 2018 B2
10154906 Granada et al. Dec 2018 B2
10159570 Metchik et al. Dec 2018 B1
10182908 Tubishevitz et al. Jan 2019 B2
10226341 Gross Mar 2019 B2
10231837 Metchik et al. Mar 2019 B1
10238493 Metchik et al. Mar 2019 B1
10245143 Gross et al. Apr 2019 B2
10245144 Metchik et al. Apr 2019 B1
10292816 Raanani et al. May 2019 B2
10299927 McLean et al. May 2019 B2
10322020 Lam et al. Jun 2019 B2
10335278 McLean et al. Jul 2019 B2
10376361 Gross Aug 2019 B2
10507108 Delgado et al. Dec 2019 B2
10507109 Metchik et al. Dec 2019 B2
10512456 Hacohen Dec 2019 B2
10517719 Miller Dec 2019 B2
10524792 Hernandez et al. Jan 2020 B2
10531866 Hariton et al. Jan 2020 B2
10575948 Iamberger et al. Mar 2020 B2
10595992 Chambers Mar 2020 B2
10595997 Metchik et al. Mar 2020 B2
10610358 Vidlund et al. Apr 2020 B2
10646342 Marr et al. May 2020 B1
10702385 Hacohen Jul 2020 B2
10758342 Chau et al. Sep 2020 B2
10813760 Metchik et al. Oct 2020 B2
10820998 Marr et al. Nov 2020 B2
10842627 Delgado et al. Nov 2020 B2
10856975 Hariton et al. Dec 2020 B2
10856978 Straubinger et al. Dec 2020 B2
10874514 Dixon et al. Dec 2020 B2
10888425 Delgado et al. Jan 2021 B2
10888644 Ratz et al. Jan 2021 B2
10905552 Dixon et al. Feb 2021 B2
10905554 Cao Feb 2021 B2
10918483 Metchik et al. Feb 2021 B2
10925732 Delgado et al. Feb 2021 B2
10945843 Delgado et al. Mar 2021 B2
10945844 McCann et al. Mar 2021 B2
10993809 McCann et al. May 2021 B2
11065114 Raanani et al. Jul 2021 B2
11083582 McCann et al. Aug 2021 B2
11147672 McCann et al. Oct 2021 B2
11179240 Delgado et al. Nov 2021 B2
11291545 Hacohen Apr 2022 B2
11291546 Gross et al. Apr 2022 B2
11291547 Gross et al. Apr 2022 B2
20010002445 Vesely May 2001 A1
20010005787 Oz et al. Jun 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010056295 Solem Dec 2001 A1
20020013571 Goldfarb et al. Jan 2002 A1
20020032481 Gabbay Mar 2002 A1
20020099436 Thornton et al. Jul 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020177894 Acosta et al. Nov 2002 A1
20030009236 Godin Jan 2003 A1
20030036791 Bonhoeffer et al. Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030060875 Wittens Mar 2003 A1
20030069635 Cartledge Apr 2003 A1
20030074052 Besselink Apr 2003 A1
20030083742 Spence et al. May 2003 A1
20030105519 Fasol et al. Jun 2003 A1
20030158578 Pantages et al. Aug 2003 A1
20040010272 Manetakis et al. Jan 2004 A1
20040030382 St. Goar et al. Feb 2004 A1
20040039414 Carley et al. Feb 2004 A1
20040039442 St. Goar et al. Feb 2004 A1
20040093060 Seguin et al. May 2004 A1
20040122503 Campbell et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040133267 Lane Jul 2004 A1
20040143315 Bruun et al. Jul 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040210244 Vargas et al. Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040220593 Greenhalgh Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040236354 Seguin Nov 2004 A1
20040249433 Freitag Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20050004668 Aklog et al. Jan 2005 A1
20050021056 St. Goar et al. Jan 2005 A1
20050027305 Shiu et al. Feb 2005 A1
20050027348 Case et al. Feb 2005 A1
20050038494 Eidenschink Feb 2005 A1
20050055086 Stobie Mar 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050080430 Wright et al. Apr 2005 A1
20050080474 Andreas et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050149160 McFerran Jul 2005 A1
20050154443 Linder et al. Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050216079 MaCoviak Sep 2005 A1
20050234508 Cummins et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050251251 Cribier Nov 2005 A1
20050256566 Gabbay Nov 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20060004439 Spenser et al. Jan 2006 A1
20060004469 Sokel Jan 2006 A1
20060015171 Armstrong Jan 2006 A1
20060020275 Goldfarb et al. Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060020333 Lashinski et al. Jan 2006 A1
20060041189 Vancaillie Feb 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060089627 Burnett et al. Apr 2006 A1
20060111773 Rittgers et al. May 2006 A1
20060116750 Herbert et al. Jun 2006 A1
20060135964 Vesley Jun 2006 A1
20060155357 Melsheimer Jul 2006 A1
20060047297 Case Aug 2006 A1
20060178700 Quinn Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060184203 Martin et al. Aug 2006 A1
20060190036 Wendel et al. Aug 2006 A1
20060190038 Carley et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060195184 Lane et al. Aug 2006 A1
20060201519 Frazier et al. Sep 2006 A1
20060212111 Case et al. Sep 2006 A1
20060216404 Seyler et al. Sep 2006 A1
20060229708 Powell et al. Oct 2006 A1
20060241656 Starksen et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060241748 Lee et al. Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060271171 McQuinn et al. Nov 2006 A1
20060282150 Olson et al. Dec 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20070016286 Herrmann et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070027528 Agnew Feb 2007 A1
20070027549 Godin Feb 2007 A1
20070038293 St. Goar et al. Feb 2007 A1
20070038295 Case et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070055340 Pryor Mar 2007 A1
20070056346 Spenser et al. Mar 2007 A1
20070078510 Ryan Apr 2007 A1
20070112422 Dehdashtian May 2007 A1
20070118151 Davidson May 2007 A1
20070162103 Case et al. Jul 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070162111 Fukamachi et al. Jul 2007 A1
20070173932 Cali et al. Jul 2007 A1
20070197858 Goldfarb et al. Aug 2007 A1
20070198077 Cully et al. Aug 2007 A1
20070198097 Zegdi Aug 2007 A1
20070213810 Newhauser et al. Sep 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070225759 Thommen et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070233186 Meng Oct 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070239272 Navia et al. Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070255400 Parravicini et al. Nov 2007 A1
20080004688 Spenser et al. Jan 2008 A1
20080004697 Lichtenstein et al. Jan 2008 A1
20080051703 Thornton et al. Feb 2008 A1
20080065204 Macoviak et al. Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080077235 Kirson Mar 2008 A1
20080082083 Forde et al. Apr 2008 A1
20080082159 Tseng et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080086164 Rowe et al. Apr 2008 A1
20080086204 Rankin Apr 2008 A1
20080091261 Long et al. Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080132989 Snow et al. Jun 2008 A1
20080140003 Bei et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080167705 Agnew Jul 2008 A1
20080167714 St. Goar et al. Jul 2008 A1
20080188929 Schreck Aug 2008 A1
20080195200 Vidlund et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255580 Hoffman et al. Oct 2008 A1
20080262609 Gross et al. Oct 2008 A1
20080269879 Sathe et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20080294234 Hartley et al. Nov 2008 A1
20090005863 Goetz Jan 2009 A1
20090036966 O'Connor et al. Feb 2009 A1
20090054969 Salahieh et al. Feb 2009 A1
20090082844 Zacharias et al. Mar 2009 A1
20090088836 Bishop et al. Apr 2009 A1
20090099554 Forster et al. Apr 2009 A1
20090099650 Bolduc et al. Apr 2009 A1
20090112159 Slattery et al. Apr 2009 A1
20090125098 Chuter May 2009 A1
20090157175 Benichou Jun 2009 A1
20090163934 Raschdorf, Jr. et al. Jun 2009 A1
20090171363 Chocron Jul 2009 A1
20090177278 Spence Jul 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090222081 Linder et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090241656 Jacquemin Oct 2009 A1
20090264859 Mas Oct 2009 A1
20090264994 Saadat Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287304 Dahlgren et al. Nov 2009 A1
20090299449 Styrc Dec 2009 A1
20090306768 Quardi Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100022823 Goldfarb et al. Jan 2010 A1
20100023117 Yoganathan et al. Jan 2010 A1
20100023120 Holecek et al. Jan 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100069852 Kelley Mar 2010 A1
20100076548 Konno Mar 2010 A1
20100100167 Bortlein et al. Apr 2010 A1
20100114299 Ben Muvhar et al. May 2010 A1
20100131054 Tuval et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20100160958 Clark Jun 2010 A1
20100161036 Pintor Jun 2010 A1
20100161042 Maisano et al. Jun 2010 A1
20100174363 Castro Jul 2010 A1
20100179643 Shalev Jul 2010 A1
20100179648 Richter et al. Jul 2010 A1
20100179649 Richter et al. Jul 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100222810 DeBeer et al. Sep 2010 A1
20100228285 Miles et al. Sep 2010 A1
20100234940 Dolan Sep 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100249917 Zhang Sep 2010 A1
20100256737 Pollock et al. Oct 2010 A1
20100262232 Annest Oct 2010 A1
20100280603 Maisano et al. Nov 2010 A1
20100280606 Naor Nov 2010 A1
20100312333 Navia et al. Dec 2010 A1
20100324595 Linder et al. Dec 2010 A1
20100331971 Keranen et al. Dec 2010 A1
20110004227 Goldfarb et al. Jan 2011 A1
20110004296 Lutter et al. Jan 2011 A1
20110015729 Jimenez et al. Jan 2011 A1
20110015731 Carpentier et al. Jan 2011 A1
20110015739 Cheung et al. Jan 2011 A1
20110022165 Oba et al. Jan 2011 A1
20110178597 Navia et al. Jan 2011 A9
20110029072 Gabbay Feb 2011 A1
20110040374 Goetz et al. Feb 2011 A1
20110040375 Letac et al. Feb 2011 A1
20110046662 Moszner et al. Feb 2011 A1
20110054466 Rothstein et al. Mar 2011 A1
20110054596 Taylor Mar 2011 A1
20110054598 Johnson Mar 2011 A1
20110066233 Thornton et al. Mar 2011 A1
20110071626 Wright et al. Mar 2011 A1
20110077730 Fentster Mar 2011 A1
20110082538 Dahlgren et al. Apr 2011 A1
20110087322 Letac et al. Apr 2011 A1
20110093063 Schreck Apr 2011 A1
20110098525 Kermode et al. Apr 2011 A1
20110106247 Miller et al. May 2011 A1
20110112625 Ben-Muvhar et al. May 2011 A1
20110112632 Chau et al. May 2011 A1
20110113768 Bauer et al. May 2011 A1
20110118830 Liddicoat et al. May 2011 A1
20110125257 Seguin et al. May 2011 A1
20110125258 Centola May 2011 A1
20110137326 Bachman Jun 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110137409 Yang et al. Jun 2011 A1
20110137410 Hacohen Jun 2011 A1
20110144742 Madrid et al. Jun 2011 A1
20110166636 Rowe Jul 2011 A1
20110172784 Richter Jul 2011 A1
20110184510 Maisano et al. Jul 2011 A1
20110190877 Lane et al. Aug 2011 A1
20110190879 Bobo et al. Aug 2011 A1
20110202076 Richter Aug 2011 A1
20110208283 Rust Aug 2011 A1
20110208293 Tabor Aug 2011 A1
20110208298 Tuval et al. Aug 2011 A1
20110213459 Garrison et al. Sep 2011 A1
20110213461 Seguin et al. Sep 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110218620 Meiri et al. Sep 2011 A1
20110224785 Hacohen Sep 2011 A1
20110238159 Guyenot et al. Sep 2011 A1
20110245911 Quill et al. Oct 2011 A1
20110245917 Savage et al. Oct 2011 A1
20110251675 Dwork Oct 2011 A1
20110251676 Sweeney et al. Oct 2011 A1
20110251678 Eidenschink et al. Oct 2011 A1
20110251679 Wiemeyer et al. Oct 2011 A1
20110251680 Tran et al. Oct 2011 A1
20110251682 Murray, III et al. Oct 2011 A1
20110251683 Tabor Oct 2011 A1
20110257721 Tabor Oct 2011 A1
20110257729 Spenser et al. Oct 2011 A1
20110257736 Marquez et al. Oct 2011 A1
20110257737 Fogarty et al. Oct 2011 A1
20110264191 Rothstein Oct 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110264198 Murray, III et al. Oct 2011 A1
20110264199 Tran et al. Oct 2011 A1
20110264200 Tran et al. Oct 2011 A1
20110264201 Yeung Oct 2011 A1
20110264202 Murray, III et al. Oct 2011 A1
20110264203 Dwork et al. Oct 2011 A1
20110264206 Tabor Oct 2011 A1
20110264208 Duffy Oct 2011 A1
20110270276 Rothstein et al. Nov 2011 A1
20110271967 Mortier et al. Nov 2011 A1
20110282438 Drews et al. Nov 2011 A1
20110282439 Thill Nov 2011 A1
20110282440 Cao Nov 2011 A1
20110283514 Fogarty et al. Nov 2011 A1
20110288632 White Nov 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110295354 Bueche et al. Dec 2011 A1
20110295363 Girard et al. Dec 2011 A1
20110301688 Dolan Dec 2011 A1
20110301698 Miller et al. Dec 2011 A1
20110301701 Padala et al. Dec 2011 A1
20110301702 Rust et al. Dec 2011 A1
20110306916 Nitzan et al. Dec 2011 A1
20110307049 Kao Dec 2011 A1
20110313452 Carley et al. Dec 2011 A1
20110313515 Quadri et al. Dec 2011 A1
20110319989 Lane Dec 2011 A1
20110319991 Hariton et al. Dec 2011 A1
20120010694 Lutter et al. Jan 2012 A1
20120022633 Olson et al. Jan 2012 A1
20120022637 Ben-Movhar et al. Jan 2012 A1
20120022639 Hacohen et al. Jan 2012 A1
20120022640 Gross et al. Jan 2012 A1
20120035703 Lutter et al. Feb 2012 A1
20120035713 Lutter et al. Feb 2012 A1
20120035722 Tuval et al. Feb 2012 A1
20120041547 Duffy et al. Feb 2012 A1
20120041551 Spenser et al. Feb 2012 A1
20120046738 Lau et al. Feb 2012 A1
20120046742 Tuval et al. Feb 2012 A1
20120053676 Ku et al. Mar 2012 A1
20120053682 Kovalsky et al. Mar 2012 A1
20120053688 Fogarty et al. Mar 2012 A1
20120059454 Millwee et al. Mar 2012 A1
20120059458 Buchbinder et al. Mar 2012 A1
20120065464 Ellis et al. Mar 2012 A1
20120078237 Wang et al. Mar 2012 A1
20120078353 Quadri et al. Mar 2012 A1
20120078357 Conklin Mar 2012 A1
20120083832 Delaloye et al. Apr 2012 A1
20120083839 Letac et al. Apr 2012 A1
20120083879 Eberhardt et al. Apr 2012 A1
20120089223 Nguyen et al. Apr 2012 A1
20120101570 Tuval et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120123511 Brown May 2012 A1
20120123529 Levi et al. May 2012 A1
20120123530 Carpentier et al. May 2012 A1
20120130473 Norris et al. May 2012 A1
20120130474 Buckley May 2012 A1
20120130475 Shaw May 2012 A1
20120136434 Carpentier et al. May 2012 A1
20120150218 Sandgren et al. Jun 2012 A1
20120165915 Melsheimer et al. Jun 2012 A1
20120165930 Gifford, III et al. Jun 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120197292 Chin-Chen et al. Aug 2012 A1
20120283824 Lutter et al. Nov 2012 A1
20120290062 McNamara et al. Nov 2012 A1
20120296360 Norris et al. Nov 2012 A1
20120296418 Bonyuet et al. Nov 2012 A1
20120300063 Majkrzak et al. Nov 2012 A1
20120310328 Olson et al. Dec 2012 A1
20120323316 Chau et al. Dec 2012 A1
20120330408 Hillukka et al. Dec 2012 A1
20130006347 McHugo Jan 2013 A1
20130018450 Hunt Jan 2013 A1
20130018458 Yohanan et al. Jan 2013 A1
20130030519 Tran et al. Jan 2013 A1
20130035759 Gross et al. Feb 2013 A1
20130041451 Patterson et al. Feb 2013 A1
20130046373 Cartledge et al. Feb 2013 A1
20130066341 Ketai et al. Mar 2013 A1
20130066342 Dell et al. Mar 2013 A1
20130079872 Gallagher Mar 2013 A1
20130116780 Miller et al. May 2013 A1
20130123896 Bloss et al. May 2013 A1
20130123900 Eblacas et al. May 2013 A1
20130150945 Crawford et al. Jun 2013 A1
20130150956 Yohanan et al. Jun 2013 A1
20130158647 Norris et al. Jun 2013 A1
20130166017 Cartledge et al. Jun 2013 A1
20130166022 Conklin Jun 2013 A1
20130172978 Vidlund et al. Jul 2013 A1
20130172992 Gross et al. Jul 2013 A1
20130178930 Straubinger et al. Jul 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130211501 Buckley et al. Aug 2013 A1
20130245742 Norris Sep 2013 A1
20130253643 Rolando et al. Sep 2013 A1
20130261737 Costello Oct 2013 A1
20130261738 Clague et al. Oct 2013 A1
20130274870 Lombardi et al. Oct 2013 A1
20130282059 Ketai et al. Oct 2013 A1
20130289711 Liddy et al. Oct 2013 A1
20130289740 Liddy et al. Oct 2013 A1
20130297013 Klima et al. Nov 2013 A1
20130304197 Buchbinder et al. Nov 2013 A1
20130304200 McLean et al. Nov 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130325114 McLean et al. Dec 2013 A1
20130331929 Mitra et al. Dec 2013 A1
20140005778 Buchbinder et al. Jan 2014 A1
20140018911 Zhou et al. Jan 2014 A1
20140031928 Murphy et al. Jan 2014 A1
20140046430 Shaw Feb 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140067050 Costello et al. Mar 2014 A1
20140067054 Chau et al. Mar 2014 A1
20140081376 Burkart et al. Mar 2014 A1
20140106951 Brandon Apr 2014 A1
20140120287 Jacoby et al. May 2014 A1
20140121749 Roeder May 2014 A1
20140121763 Duffy et al. May 2014 A1
20140135894 Norris et al. May 2014 A1
20140135895 Andress et al. May 2014 A1
20140142681 Norris May 2014 A1
20140142688 Duffy et al. May 2014 A1
20140148891 Johnson May 2014 A1
20140163690 White Jun 2014 A1
20140172069 Roeder et al. Jun 2014 A1
20140172077 Bruchman et al. Jun 2014 A1
20140172082 Bruchman et al. Jun 2014 A1
20140188210 Beard et al. Jul 2014 A1
20140188221 Chung et al. Jul 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140194983 Kovalsky et al. Jul 2014 A1
20140207231 Hacohen Jul 2014 A1
20140214157 Bortlein et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140249622 Carmi et al. Sep 2014 A1
20140257461 Robinson et al. Sep 2014 A1
20140257467 Lane Sep 2014 A1
20140257475 Gross et al. Sep 2014 A1
20140257476 Montorfano et al. Sep 2014 A1
20140277358 Slazas Sep 2014 A1
20140277409 Bortlein et al. Sep 2014 A1
20140277412 Börtlein et al. Sep 2014 A1
20140277418 Miller Sep 2014 A1
20140277422 Ratz et al. Sep 2014 A1
20140277427 Ratz et al. Sep 2014 A1
20140296962 Cartledge et al. Oct 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140331475 Duffy et al. Nov 2014 A1
20140336744 Tani et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20140358222 Gorman, III et al. Dec 2014 A1
20140358224 Tegels et al. Dec 2014 A1
20140379065 Johnson et al. Dec 2014 A1
20140379074 Spence et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150018944 O'Connor et al. Jan 2015 A1
20150032205 Matheny Jan 2015 A1
20150045880 Hacohen Feb 2015 A1
20150045881 Lim Feb 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150119970 Nakayama et al. Apr 2015 A1
20150127097 Neumann et al. May 2015 A1
20150142100 Morriss et al. May 2015 A1
20150142103 Vidlund May 2015 A1
20150157457 Hacohen Jun 2015 A1
20150164640 McLean et al. Jun 2015 A1
20150173896 Richter Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150196390 Ma et al. Jul 2015 A1
20150196393 Vidlund et al. Jul 2015 A1
20150216661 Hacohen et al. Aug 2015 A1
20150238313 Spence et al. Aug 2015 A1
20150245934 Lombardi et al. Sep 2015 A1
20150250588 Yang et al. Sep 2015 A1
20150272730 Melnick Oct 2015 A1
20150272731 Racchini et al. Oct 2015 A1
20150272734 Sheps et al. Oct 2015 A1
20150282964 Beard et al. Oct 2015 A1
20150320556 Levi et al. Nov 2015 A1
20150327994 Morriss Nov 2015 A1
20150328000 Ratz et al. Nov 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150342736 Rabito et al. Dec 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150351904 Cooper et al. Dec 2015 A1
20150351906 Hammer et al. Dec 2015 A1
20150359629 Ganesan et al. Dec 2015 A1
20160030169 Shahriari Feb 2016 A1
20160030171 Quijano et al. Feb 2016 A1
20160089482 Siegenthaler Mar 2016 A1
20160095700 Righini Apr 2016 A1
20160100939 Armstrong et al. Apr 2016 A1
20160106539 Buchbinder et al. Apr 2016 A1
20160113766 Ganesan et al. Apr 2016 A1
20160113768 Ganesan et al. Apr 2016 A1
20160125160 Heneghan et al. May 2016 A1
20160157862 Hernandez et al. Jun 2016 A1
20160175095 Dienno et al. Jun 2016 A1
20160213473 Hacohen et al. Jul 2016 A1
20160220367 Barrett Aug 2016 A1
20160228247 Maimon et al. Aug 2016 A1
20160242902 Morriss et al. Aug 2016 A1
20160270911 Ganesan et al. Sep 2016 A1
20160296330 Hacohen Oct 2016 A1
20160310268 Oba et al. Oct 2016 A1
20160310274 Gross et al. Oct 2016 A1
20160317301 Quadri et al. Nov 2016 A1
20160324633 Gross et al. Nov 2016 A1
20160324635 Vidlund et al. Nov 2016 A1
20160324640 Gifford et al. Nov 2016 A1
20160331526 Schweich et al. Nov 2016 A1
20160331527 Vidlund et al. Nov 2016 A1
20160338706 Rowe Nov 2016 A1
20160367360 Cartledge et al. Dec 2016 A1
20160374801 Jimenez et al. Dec 2016 A1
20170042678 Ganesan et al. Feb 2017 A1
20170049435 Sauer et al. Feb 2017 A1
20170056166 Ratz et al. Mar 2017 A1
20170056171 Cooper et al. Mar 2017 A1
20170065407 Hacohen et al. Mar 2017 A1
20170065411 Grundeman et al. Mar 2017 A1
20170100236 Robertson et al. Apr 2017 A1
20170128205 Tamir et al. May 2017 A1
20170196688 Christianson et al. Jul 2017 A1
20170196692 Kirk et al. Jul 2017 A1
20170209264 Chau et al. Jul 2017 A1
20170216026 Quill et al. Aug 2017 A1
20170224323 Rowe et al. Aug 2017 A1
20170231757 Gassler Aug 2017 A1
20170231759 Geist et al. Aug 2017 A1
20170231760 Lane et al. Aug 2017 A1
20170231766 Hariton et al. Aug 2017 A1
20170239048 Goldfarb et al. Aug 2017 A1
20170252159 Hacohen et al. Sep 2017 A1
20170266003 Hammer et al. Sep 2017 A1
20170333183 Backus Nov 2017 A1
20170333187 Hariton et al. Nov 2017 A1
20170360426 Hacohen et al. Dec 2017 A1
20170367823 Hariton et al. Dec 2017 A1
20180000580 Wallace et al. Jan 2018 A1
20180014930 Hariton et al. Jan 2018 A1
20180014932 Hammer et al. Jan 2018 A1
20180021129 Peterson et al. Jan 2018 A1
20180028215 Cohen Feb 2018 A1
20180049873 Manash et al. Feb 2018 A1
20180055628 Patel et al. Mar 2018 A1
20180055630 Patel et al. Mar 2018 A1
20180098850 Rafiee et al. Apr 2018 A1
20180116790 Ratz et al. May 2018 A1
20180116843 Schreck et al. May 2018 A1
20180125644 Conklin May 2018 A1
20180132999 Perouse May 2018 A1
20180147059 Hammer et al. May 2018 A1
20180153687 Hariton et al. Jun 2018 A1
20180153689 Maimon et al. Jun 2018 A1
20180161159 Lee et al. Jun 2018 A1
20180177594 Patel et al. Jun 2018 A1
20180214263 Rolando et al. Aug 2018 A1
20180243086 Barbarino et al. Aug 2018 A1
20180250147 Syed Sep 2018 A1
20180296333 Dixon et al. Oct 2018 A1
20180296341 Noe et al. Oct 2018 A1
20180344457 Gross et al. Dec 2018 A1
20180360457 Ellis et al. Dec 2018 A1
20190000613 Delgado et al. Jan 2019 A1
20190015200 Delgado et al. Jan 2019 A1
20190021852 Delgado et al. Jan 2019 A1
20190083261 Perszyk et al. Mar 2019 A1
20190167423 Hariton et al. Jun 2019 A1
20190183644 Hacohen Jun 2019 A1
20190192295 Spence et al. Jun 2019 A1
20190321172 Gross et al. Oct 2019 A1
20190336280 Naor Nov 2019 A1
20200000449 Goldfarb et al. Jan 2020 A1
20200030098 Delgado et al. Jan 2020 A1
20200054335 Hernandez et al. Feb 2020 A1
20200113677 McCann et al. Apr 2020 A1
20200113689 McCann et al. Apr 2020 A1
20200113692 McCann et al. Apr 2020 A1
20200138567 Marr et al. May 2020 A1
20200163761 Hariton et al. May 2020 A1
20200214832 Metchik et al. Jul 2020 A1
20200237512 McCann et al. Jul 2020 A1
20200246136 Marr et al. Aug 2020 A1
20200246140 Hariton et al. Aug 2020 A1
20200253600 Darabian Aug 2020 A1
20200261094 Goldfarb et al. Aug 2020 A1
20200315786 Metchik et al. Oct 2020 A1
20200337842 Metchik et al. Oct 2020 A1
20210093449 Hariton et al. Apr 2021 A1
20210113331 Quadri et al. Apr 2021 A1
20210137680 Kizuka et al. May 2021 A1
20210259835 Tyler, II et al. Aug 2021 A1
20220000612 Hacohen Jan 2022 A1
Foreign Referenced Citations (105)
Number Date Country
2822801 Aug 2006 CA
103974674 Aug 2014 CN
0170262 Feb 1986 EP
1264582 Dec 2002 EP
1637092 Mar 2006 EP
1768630 Jan 2015 EP
2349124 Oct 2018 EP
2739214 Oct 2018 EP
3583922 Dec 2019 EP
3270825 Apr 2020 EP
2485795 Sep 2020 EP
S53152790 Dec 1978 JP
20010046894 Jun 2001 KR
1998043557 Oct 1998 WO
1999030647 Jun 1999 WO
2000047139 Aug 2000 WO
2001062189 Aug 2001 WO
0182832 Nov 2001 WO
2003020179 Mar 2003 WO
2003028558 Apr 2003 WO
2004028399 Apr 2004 WO
2004108191 Dec 2004 WO
2005107650 Nov 2005 WO
2006007389 Jan 2006 WO
2006007401 Jan 2006 WO
2006054930 May 2006 WO
2006070372 Jul 2006 WO
2006086434 Aug 2006 WO
2006089236 Aug 2006 WO
2006116558 Nov 2006 WO
2006128193 Nov 2006 WO
2007047488 Apr 2007 WO
2007059252 May 2007 WO
2008013915 Jan 2008 WO
2008029296 Mar 2008 WO
2008070797 Jun 2008 WO
2008103722 Aug 2008 WO
09033469 Mar 2009 WO
2009053497 Apr 2009 WO
2009091509 Jul 2009 WO
2010006627 Jan 2010 WO
2010027485 Mar 2010 WO
2010037141 Apr 2010 WO
2010045297 Apr 2010 WO
2010057262 May 2010 WO
2010073246 Jul 2010 WO
2010081033 Jul 2010 WO
2010121076 Oct 2010 WO
2011025972 Mar 2011 WO
2011069048 Jun 2011 WO
2011089601 Jul 2011 WO
2011106137 Sep 2011 WO
2011111047 Sep 2011 WO
0187190 Nov 2011 WO
2011137531 Nov 2011 WO
2011-143263 Nov 2011 WO
2011144351 Nov 2011 WO
2011154942 Dec 2011 WO
2012011108 Jan 2012 WO
2012024428 Feb 2012 WO
2012036740 Mar 2012 WO
2012048035 Apr 2012 WO
2012127309 Sep 2012 WO
2012177942 Dec 2012 WO
2013021374 Feb 2013 WO
2013021375 Feb 2013 WO
2013021384 Feb 2013 WO
2013059747 Apr 2013 WO
2013078497 Jun 2013 WO
2013114214 Aug 2013 WO
2013128436 Sep 2013 WO
2013175468 Nov 2013 WO
2014022124 Feb 2014 WO
2014076696 May 2014 WO
2014115149 Jul 2014 WO
2014121280 Aug 2014 WO
2014144937 Sep 2014 WO
2014145338 Sep 2014 WO
2014164364 Oct 2014 WO
2014194178 Dec 2014 WO
2015173794 Nov 2015 WO
2016016899 Feb 2016 WO
2016093877 Jun 2016 WO
2016125160 Aug 2016 WO
2017223486 Dec 2017 WO
2018025260 Feb 2018 WO
2018025263 Feb 2018 WO
2018029680 Feb 2018 WO
2018039631 Mar 2018 WO
2018106837 Jun 2018 WO
2018112429 Jun 2018 WO
2018118717 Jun 2018 WO
2018131042 Jul 2018 WO
2018131043 Jul 2018 WO
2019026059 Feb 2019 WO
2019027507 Feb 2019 WO
2019030753 Feb 2019 WO
2019077595 Apr 2019 WO
2019116369 Jun 2019 WO
2019138400 Jul 2019 WO
2019202579 Oct 2019 WO
2020058972 Mar 2020 WO
2020167677 Aug 2020 WO
2021156866 Aug 2021 WO
2021186424 Sep 2021 WO
Non-Patent Literature Citations (249)
Entry
European Search Report dated Jun. 10, 2021 which issued during the prosecution of Applicant's European App No. 21157988.3.
An Invitation to pay additional fees dated May 19, 2021, which issued during the prosecution of Applicant's PCT/IL2021/050132.
An International Search Report and a Written Opinion both dated Jul. 12, 2021, which issued during the prosecution of Applicant's PCT/IL2021/050132.
IPR2021-00383 Petitioners' Authorized Reply to Patent Owner's Preliminary Response dated May 27, 2021.
Exhibit 1014—Transcript of proceedings held May 20, 2021 (Edwards Lifesciences vs. Cardiovalve).
Exhibit 1015—Facilitate, Meriam-Webster.com, https://www.merriamwebster.com/dictionary/facilitate (visited May 26, 2021).
Patent Owner's Authorized Surreply to Petitioner's Reply to Patent Owner's Preliminary Response dated Jun. 4, 2021 (Edwards Lifesciences vs. Cardiovalve).
An Office Action dated Aug. 18, 2021, which issued during the prosecution of U.S. Appl. No. 17/210,183.
Institution decision dated Jul. 20, 2021 (Edwards Lifesciences vs. Cardiovalve).
An Office Action dated Sep. 9, 2021, which issued during the prosecution of U.S. Appl. No. 16/768,909.
An Office Action dated Sep. 15, 2021, which issued during the prosecution of U.S. Appl. No. 16/135,599.
An Office Action dated Oct. 14, 2021, which issued during the prosecution of U.S. Appl. No. 16/680,739.
An Office Action dated Oct. 21, 2021, which issued during the prosecution of U.S. Appl. No. 17/335,845.
European Search Report dated Oct. 11, 2021 which issued during the prosecution of Applicant's European App No. 21176010.3.
Fann, James I., et al. “Beating heart catheter-based edge-to-edge mitral valve procedure in a porcine model: efficacy and healing response.” Circulation 110.8 (2004): 988-993.
Feldman, Ted, et al. “Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort.” Journal of the American College of Cardiology 54.8 (2009): 686-694.
IPR2021-00383 Patent Owner's Contingent Motion to Amend Under 37 C.F.R. §42.121 dated Oct. 13, 2021.
IPR2021-00383 Patent Owner's Response Pursuant to 37 C.F.R. § 42.120 dated Oct. 13, 2021.
IPR2021-00383 Second Declaration of Dr. Michael Sacks dated Oct. 13, 2021.
An Office Action dated Oct. 21, 2021, which issued during the prosecution of U.S. Appl. No. 17/306,231.
Maisano, Francesco, et al. “The evolution from surgery to percutaneous mitral valve interventions: the role of the edge-to-edge technique.” Journal of the American College of Cardiology 58.21 (2011): 2174-2182.
IPR2021-00383 Deposition of Dr. Ivan Vesely, dated Sep. 22, 2021.
Cardiovalve Exhibit 2009—Percutaneous Mitral Leaflet Repair: MitraClip® Therapy for Mitral Regurgitation (2012).
Feldman, Ted, et al. “Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial.” Journal of the American College of Cardiology 46.11 (2005): 2134-2140.
An Office Action summarized English translation and Search Report dated Oct. 8, 2021, which issued during the prosecution of Chinese Patent Application No. 201780061210.3.
An Office Action dated Nov. 4, 2021, which issued during the prosecution of U.S. Appl. No. 17/366,711.
An Office Action summarized English translation and Search Report dated Aug. 12, 2021, which issued during the prosecution of Chinese Patent Application No. 201880058940.2.
Poirier, Nancy C., et al. “A novel repair for patients with atrioventricular septal defect requiring reoperation for left atrioventricular valve regurgitation.” European journal of cardio-thoracic surgery 18.1 (2000): 54-61.
An Office Action dated Mar. 29, 2021, which issued during the prosecution of U.S. Appl. No. 16/738,516.
Ando, Tomo, et al. “Iatrogenic ventricular septal defect following transcatheter aortic valve replacement: a systematic review.” Heart, Lung and Circulation 25.10 (2016): 968-974.
Urena, Marina, et al. “Transseptal transcatheter mitral valve replacement using balloon-expandable transcatheter heart valves: a step-by-step approach.” JACC: Cardiovascular Interventions 10.19 (2017): 1905-1919.
An English summary of an Official Action dated Mar. 29, 2021, which issued during the prosecution of Chinese Patent Application No. 201780061210.3.
An International Search Report and a Written Opinion both dated Jan. 28, 2020, which issued during the prosecution of Applicant's PCT/IL2019/051031.
An International Preliminary Report on Patentability dated Mar. 9, 2021, which issued during the prosecution of Applicant's PCT/IL2019/051031.
An Office Action dated May 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/636,204.
Notice of Allowance dated May 17, 2021, which issued during the prosecution of U.S. Appl. No. 16/138,129.
Notice of Allowance dated Jun. 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/802,353.
An Office Action dated May 12, 2021, which issued during the prosecution of Canadian Patent Application No. 2,973,940.
Petition for Inter Partes Review of U.S. Pat. No. 10,702,385—dated Jun. 4, 2021.
Declaration of Ivan Vesely, Ph.D. in Support of Petition for Inter Partes Review of U.S. Pat. No. 10,702,385—dated Jun. 4, 2021.
An Office Action dated Nov. 23, 2012, which issued during the prosecution of U.S. Appl. No. 13/033,852.
An Office Action dated Dec. 31, 2012, which issued during the prosecution of U.S. Appl. No. 13/044,694.
An Office Action dated Feb. 6, 2013, which issued during the prosecution of U.S. Appl. No. 13/412,814.
Langer F et al., “RING plus STRING: Papillary muscle repositioning as an adjunctive repair technique for ischemic mitral regurgitation,” J Thorac Cardiovasc Surg 133:247-9, Jan. 2007.
Langer F et al., “RING+STRING: Successful repair technique for ischemic mitral regurgitation with severe leaflet tethering,” Circulation 120[suppl 1]: S85-S91, Sep. 2009.
J Webb et al., “Transcatheter Valve-in-Valve Implantation for Failed Bioprosthetic Heart Valves”, Circulation. Apr. 2010; 121: 1848-1857.
Jansen, J., Willeke, S., Reul, H. and Rum, G. (1992), “Detachable Shape-Memory Sewing Ring for Heart Valves.” Artificial Organs, 16:294-297. 1992 (an abstract).
Alexander S. Geha, et al., “Replacement of degenerated mitral and aortic bioprostheses without explanation”, Ann Thorac Surg. Jun. 2001; 72:1509-1514.
An International Search Report and a Written Opinion both dated Oct. 13, 2011 which issued during the prosecution of Applicant's PCT/IL11/00231.
An Office Action dated Jul. 1, 2016, which issued during the prosecution of U.S. Appl. No. 14/161,921.
An International Search Report and a Written Opinion both dated Dec. 5, 2011, which issued during the prosecution of Applicant's PCT/IL11/00582.
An Office Action dated May 29, 2012, which issued during the prosecution of U.S. Appl. No. 12/840,463.
U.S. Appl. No. 61/555,160, filed Nov. 3, 2011.
U.S. Appl. No. 61/525,281, filed Aug. 19, 2011.
U.S. Appl. No. 61/537,276, filed Sep. 21, 2011.
U.S. Appl. No. 61/515,372, filed Aug. 5, 2011.
U.S. Appl. No. 61/492,449, filed Jun. 2, 2011.
U.S. Appl. No. 61/588,892, filed Jan. 20, 2012.
An International Search Report and a Written Opinion both dated Feb. 6, 2013, which issued during the prosecution of Applicant's PCT/IL12/00292.
An International Search Report and a Written Opinion both dated Feb. 6, 2013, which issued during the prosecution of Applicant's PCT/IL12/00293.
An Office Action dated Nov. 28, 2012, which issued during the prosecution of U.S. Appl. No. 12/961,721.
An Office Action dated Feb. 15, 2013, which issued during the prosecution of U.S. Appl. No. 12/840,463.
An Office Action dated Feb. 10, 2014, which issued during the prosecution of U.S. Appl. No. 13/033,852.
An Office Action dated Sep. 19, 2014, which issued during the prosecution of U.S. Appl. No. 13/044,694.
An International Search Report and a Written Opinion both dated Sep. 4, 2014 which issued during the prosecution of Applicant's PCT/IL2014/050087.
Invitation to Pay Additional Fees dated Jun. 12, 2014 PCT/IL2014/050087.
An Office Action dated Jun. 17, 2014, which issued during the prosecution of U.S. Appl. No. 12/961,721.
An Office Action dated Jul. 3, 2014, which issued during the prosecution of U.S. Appl. No. 13/033,852.
An Office Action dated May 23, 2014, which issued during the prosecution of U.S. Appl. No. 13/412,814.
Dominique Himbert; “Mitral Regurgitation and Stenosis from Bioprosthesis and Annuloplasty Failure: Transcatheter approaches and outcomes”, 24 pages Oct. 28, 2013.
An International Search Report and a Written Opinion both dated Mar. 17, 2014 which issued during the prosecution of Applicant's PCT/IL2013/050937.
An International Preliminary Report on patentabilty dated Dec. 2, 2013, which issued during the prosecution of Applicant's PCT/IL11/00582.
An Office Action dated Sep. 12, 2013, which issued during the prosecution of U.S. Appl. No. 13/412,814.
An Office Action dated Aug. 2, 2013, which issued during the prosecution of U.S. Appl. No. 13/033,852.
An International Preliminary Report on patentabilty dated Sep. 11, 2012, which issued during the prosecution of Applicant's PCT/IL2011/000231.
An Office Action dated Jul. 2, 2014, which issued during the prosecution of U.S. Appl. No. 13/811,308.
An Office Action dated Jan. 20, 2016, which issued during the prosecution of U.S. Appl. No. 14/161,921.
An Office Action dated Jul. 23, 2013, which issued during the prosecution of U.S. Appl. No. 12/961,721.
An Office Action dated Jul. 18, 2013, which issued during the prosecution of U.S. Appl. No. 13/044,694.
An Office Action dated Nov. 8, 2013, which issued during the prosecution of U.S. Appl. No. 12/840,463.
An Office Action dated Jun. 4, 2014, which issued during the prosecution of U.S. Appl. No. 12/840,463.
An Office Action dated Aug. 13, 2012, which issued during the prosecution of U.S. Appl. No. 13/044,694.
An Office Action dated Jul. 2, 2012, which issued during the prosecution of U.S. Appl. No. 13/033,852.
An Office Action dated Feb. 3, 2014, which issued during the prosecution of U.S. Appl. No. 13/811,308.
An International Preliminary Report on patentabilty dated Feb. 11, 2014, which issued during the prosecution of Applicant's PCT/IL12/00292.
An International Preliminary Report on patentabilty dated Feb. 11, 2014, which issued during the prosecution of Applicant's PCT/IL12/00293.
A Notice of Allowance dated Aug. 15, 2014, which issued during the prosecution of U.S. Appl. No. 13/412,814.
An Office Action dated Aug. 14, 2012, which issued during the prosecution of U.S. Appl. No. 12/961,721.
U.S. Appl. No. 61/283,819, filed Dec. 8, 2009.
Notice of Allowance dated Apr. 8, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258.
U.S. Appl. No. 61/756,034, filed Jan. 24, 2013.
U.S. Appl. No. 61/756,049, filed Jan. 24, 2013.
An International Preliminary Report on Patentability dated Jan. 31, 2017, which issued during the prosecution of Applicant's PCT/IL2015/050792.
U.S. Appl. No. 61/312,412, filed Mar. 10, 2010.
U.S. Appl. No. 62/139,854, filed Mar. 30, 2015.
Notice of Allowance dated Apr. 20, 2018, which issued during the prosecution of U.S. Appl. No. 15/878,206.
An Office Action dated Dec. 10, 2015, which issued during the prosecution of U.S. Appl. No. 14/237,258.
An International Preliminary Report on Patentability dated Jul. 28, 2015, which issued during the prosecution of Applicant's PCT/IL2014/050087.
An Office Action dated Nov. 27, 2015, which issued during the prosecution of U.S. Appl. No. 14/626,267.
An Office Action dated Jan. 21, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,264.
An Office Action dated Jan. 30, 2015, which issued during the prosecution of UK Patent Application No. 1413474.6.
An International Search Report and a Written Opinion both dated May 30, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050125.
An Office Action dated Sep. 26, 2016, which issued during the prosecution of U.S. Appl. No. 14/763,004.
An Office Action dated Jan. 18, 2017, which issued during the prosecution of U.S. Appl. No. 14/626,267.
An Office Action dated Feb. 7, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608.
An Office Action dated Feb. 8, 2017, which issued during the prosecution of UK Patent Application No. 1613219.3.
An Office Action together dated Feb. 10, 2017, which issued during the prosecution of European Patent Application No. 12821522.5.
An International Search Report and a Written Opinion both dated Oct. 27, 2015, which issued during the prosecution of Applicant's PCT/IL2015/050792.
European Search Report dated Feb. 18, 2015, which issued during the prosecution of Applicant's European App No. 12821522.5.
Saturn Project—a novel solution for transcatheter heart valve replacement specifically designed to address clinical therapeutic needs on mitral valve: Dec. 2016.
Righini presentation EuroPCR May 2015 (Saturn)—(downloaded from: https://www.pcronline.com/Cases-resourcesimages/Resources/Course-videos-slides/2015/Cardiovascularinnovation-pipeline-Mitral-and-tricuspid-valve-interventions).
An Advisory Action dated Apr. 2, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004.
An Office Action dated Jul. 26, 2018, which issued during the prosecution of U.S. Appl. No. 15/872,501.
An Office Action dated May 4, 2018, which issued during the prosecution of U.S. Appl. No. 15/872,501.
An Office Action dated Apr. 20, 2018, which issued during the prosecution of U.S. Appl. No. 15/886,517.
An Office Action dated Aug. 9, 2018, which issued during the prosecution of U.S. Appl. No. 15/899,858.
An Office Action dated Aug. 9, 2018, which issued during the prosecution of U.S. Appl. No. 15/902,403.
An Office Action dated Jun. 28, 2018, which issued during the prosecution of Design U.S. Appl. No. 29/635,658.
An Office Action dated Jun. 28, 2018, which issued during the prosecution of Design U.S. Appl. No. 29/635,661.
U.S. Appl. No. 62/030,715, filed Jul. 30, 2014.
An Office Action dated Jun. 6, 2018, which issued dunng the prosecution of UK Patent Application No. 1720803.4.
An International Search Report and a Written Opinion both dated Jun. 20, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050024.
An Office Action dated Jun. 18, 2018, which issued during the prosecution of UK Patent Application No. 1800399.6.
An Office Action dated Oct. 23, 2017, which issued during the prosecution of U.S. Appl. No. 14/763,004.
An Office Action dated Dec. 7, 2017, which issued during the prosecution of U.S. Appl. No. 15/213,791.
Interview Summary dated Feb. 8, 2018, which issued during the prosecution of U.S. Appl. No. 15/213,791.
An Office Action dated Feb. 7, 2018, which issued during the prosecution of U.S. Appl. No. 15/197,069.
An Office Action dated Jan. 5, 2018, which issued during the prosecution of U.S. Appl. No. 15/541,783.
An Office Action dated Feb. 2, 2018, which issued during the prosecution of U.S. Appl. No. 15/329,920.
An Invitation to pay additional fees dated Jan. 2, 2018, which issued during the prosecution of Applicant's PCT/IL2017/050849.
An Invitation to pay additional fees dated Sep. 29, 2017, which issued during the prosecution of Applicant's PCT/IL2017/050873.
European Search Report dated Jun. 29, 2017, which issued during the prosecution of Applicant's European App No. 11809374.9.
An Invitation to pay additional fees dated Oct. 11, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050725.
An Office Action dated Dec. 4, 2018, which issued during the prosecution of U.S. Appl. No. 16/045,059.
An Office Action together with the English translation dated Nov. 5, 2018 which issued during the prosecution of Chinese Patent Application No. 201680008328.5.
Notice of Allowance dated Sep. 25, 2018, which issued during the prosecution of U.S. Appl. No. 15/188,507.
European Search Report dated Sep. 26, 2018 which issued during the prosecution of Applicant's European App No. 18186784.7.
An Office Action dated Jun. 30, 2015, which issued during the prosecution of U.S. Appl. No. 14/522,987.
An Office Action dated Sep. 29, 2017, which issued during the prosecution of U.S. Appl. No. 15/197,069.
Notice of Allowance dated Oct. 30, 2018, which issued dunng the prosecution of U.S. Appl. No. 15/197,069.
An Office Action dated Jan. 17, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004.
An Office Action dated Mar. 25, 2015, which issued during the prosecution of U.S. Appl. No. 12/840,463.
An Office Action dated Feb. 25, 2016, which issued during the prosecution of U.S. Appl. No. 14/522,987.
An Office Action dated Apr. 13, 2016, which issued during the prosecution of U.S. Appl. No. 14/626,267.
An Office Action dated Aug. 28, 2015, which issued during the prosecution of U.S. Appl. No. 14/237,264.
An Office Action dated Apr. 21, 2017, which issued during the prosecution of U.S. Appl. No. 15/213,791.
Maisano (2015) TCR presentation re Cardiovalve.
Notice of Allowance dated Nov. 19, 2018, which issued during the prosecution of U.S. Appl. No. 15/197,069.
Notice of Allowance dated May 10, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258.
Notice of Allowance dated May 20, 2016, which issued during the prosecution of U.S. Appl. No. 14/237,258.
Notice of Allowance dated Jul. 6, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608.
Notice of Allowance dated Aug. 18, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608.
Notice of Allowance dated May 22, 2017, which issued during the prosecution of U.S. Appl. No. 14/689,608.
Notice of Allowance dated Feb. 11, 2015, which issued during the prosecution of U.S. Appl. No. 13/033,852.
Notice of Allowance dated May 5, 2015, which issued during the prosecution of U.S. Appl. No. 12/840,463.
Notice of Allowance dated Mar. 10, 2015, which issued during the prosecution of U.S. Appl. No. 13/811,308.
Notice of Allowance dated Mar. 18, 2020, which issued during the prosecution of U.S. Appl. No. 16/284,331.
An Office Action dated Jan. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/284,331.
An International Search Report and a Written Opinion both dated Nov. 9, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050869.
An Office Action dated Jun. 25, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920.
An International Search Report and a Written Opinion both dated May 13, 2019, which issued during the prosecution of Applicant's PCT/IL2018/051350.
An International Search Report and a Written Opinion both dated Apr. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2019/050142.
An International Search Report and a Written Opinion both dated Jan. 25, 2019, which issued during the prosecution of Applicant's PCT/IL2018/051122.
An International Search Report and a Written Opinion both dated Dec. 5, 2018, which issued during the prosecution of Applicant's PCT/IL2018/050725.
An International Preliminary Report on Patentability dated Feb. 12, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050873
An International Preliminary Report on Patentability dated Feb. 5, 2019, which issued during the prosecution of Applicant's PCT/IL2017/050849.
An Office Action dated Nov. 26, 2019, which issued during the prosecution of U.S. Appl. No. 16/532,945.
An Office Action dated Nov. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501.
An Office Action dated Mar. 25, 2019, which issued during the prosecution of European Patent Application No. 14710060.6.
An Office Action dated Oct. 25, 2018, which issued during the prosecution of U.S. Appl. No. 14/763,004.
An Office Action dated Mar. 4, 2019, which issued during the prosecution of U.S. Appl. No. 14/763,004.
An Office Action dated Jan. 9, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920.
An Office Action dated Jan. 30, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501.
An Office Action dated Feb. 5, 2019, which issued during the prosecution of U.S. Appl. No. 15/899,858.
An Office Action dated May 23, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659.
An Office Action dated May 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/691,032.
An Office Action dated May 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/433,547.
An Office Action dated Aug. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,559.
An Office Action dated Aug. 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659.
An Office Action dated Jun. 19, 2019, which issued during the prosecution of U.S. Appl. No. 15/682,789.
An Office Action dated Jun. 14, 2019, which issued during the prosecution of U.S. Appl. No. 15/703,385.
An Office Action dated Oct. 4, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140.
An Office Action dated Jun. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/388,038.
An Office Action dated Sep. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/460,313.
Serruys, P. W., Piazza, N., Cribier, A., Webb, J., Laborde, J. C., & de Jaegere, P. (Eds.). (2009). Transcatheter aortic valve implantation: tips and tricks to avoid failure. CRC Press.—Screenshots from Google Books downloaded from: https://books.google.co.il/books?id=FLzLBQAAQBAJ&1pg=PA198&ots=soqWrDH-y_&dq=%20%22Edwards%20SAPIEN%22&lr&pg=PA20#v=onepage&q=%22Edwards%20SAPIEN%22&f=false ; Downloaded on Jun. 18, 2020.
An Office Action dated Dec. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/144,054.
An Office Action dated Feb. 2, 2021, which issued during the prosecution of U.S. Appl. No. 16/811,732.
An Office Action dated Jan. 13, 2021, which issued during the prosecution of European Patent Application No. 15751089.2.
Maisano, F., et al. “The edge-to-edge technique: a simplified method to correct mitral insufficiency.” European journal of cardio-thoracic surgery 13.3 (1998): 240-246.
Declaration of Dr. Ivan Vesely, Ph.D. in Support of Petition for Inter Partes Review of U.S. Pat. No. 10,226,341—dated Dec. 17, 2020.
Petition for Inter Partes Review of U.S. Pat. No. 10,226,341 and Exhibits 1001-1013—dated Dec. 29, 2020.
An Office Action together with an English summary dated Mar. 3, 2021, which issued during the prosecution of Chinese Patent Application No. 201780047391.4.
Fucci, C., et al. “Improved results with mitral valve repair using new surgical techniques.” European journal of cardio-thoracic surgery 9.11 (1995): 621-627.
Declaration of Ivan Vesely, Ph.D., in Support of Petition for Inter Partesreview of U.S. Pat. No. 7,563,267—dated May 29, 2019.
U.S. Appl. No. 60/128,690, filed Apr. 9, 1999.
Batista, Randas JV, et al. “Partial left ventriculectomy to treat end-stage heart disease.” The Annals of thoracic surgery 64.3 (1997): 634-638.
Beall Jr, Arthur C., et al. “Clinical experience with a dacron velour-covered teflon-disc mitral-valve prosthesis.” The Annals of thoracic surgery 5.5 (1968): 402-410.
Kalbacher, D., et al. “1000 MitraClip™ procedures: Lessons learnt from the largest single-centre experience worldwide.” (2019): 3137-3139.
U.S. Appl. No. 60/613,867, filed Sep. 27, 2004.
Mitral Valve Academic Research Consortium. “Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles a Consensus Document from the Mitral Valve Academic Research Consortium.” Journal of the American College of Cardiology 66.3 (2015): 278-307.
IPR2021-00383 Final Written Decision dated Jul. 18, 2022.
IPR2021-01051 Preliminary Guidance Patent Owner's Motion to Amend dated Jun. 24, 2022.
An Office Action dated Jun. 28, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,969.
An Office Action dated Jul. 8, 2022, which issued during the prosecution of U.S. Appl. No. 16/144,054.
An International Search Report and a Written Opinion both dated May 3, 2022, which issued during the prosecution of Applicant's PCT/IL2021/051433.
An Office Action together with an English Summary dated May 7, 2022 which issued during the prosecution of Chinese Patent Application No. 201880058940.2.
Ex Parte Quayle dated May 2, 2022, which issued during the prosecution of U.S. Appl. No. 16/879,952.
Notice of Allowance dated May 4, 2022, which issued during the prosecution of U.S. Appl. No. 16/680,739.
Notice of Allowance dated Jan. 31, 2022, which issued during the prosecution of U.S. Appl. No. 17/479,418.
An Office Action dated Mar. 18, 2022, which issued during the prosecution of U.S. Appl. No. 16/746,489.
Notice of Allowance dated Mar. 22, 2022, which issued during the prosecution of U.S. Appl. No. 17/366,711.
Notice of Allowance dated Mar. 4, 2022, which issued during the prosecution of U.S. Appl. No. 16/768,909.
An Office Action dated Dec. 9, 2021, which issued during the prosecution of U.S. Appl. No. 16/135,969.
An Office Action dated Jan. 24, 2022, which issued during the prosecution of U.S. Appl. No. 16/135,466.
An Office Action dated Apr. 11, 2022, which issued during the prosecution of U.S. Appl. No. 17/473,472.
IPR2021-00383 Preliminary Guidance dated Jan. 31, 2022.
An International Preliminary Report on Patentability dated Oct. 20, 2020, which issued during the prosecution of Applicant's PCT/IL2019/050142.
An Office Action dated Oct. 5, 2020, which issued during the prosecution of Canadian Patent Application No. 2,973,940.
Notice of Allowance dated Nov. 19, 2020, which issued during the prosecution of U.S. Appl. No. 16/318,025.
An Office Action dated Sep. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/811,732.
An Office Action summarized English translation and Search Report dated Nov. 25, 2020, which issued during the prosecution of Chinese Patent Application No. 201910449820.1.
An Office Action dated Nov. 30, 2020, which issued during the prosecution of U.S. Appl. No. 16/138,129.
An Office Action dated Nov. 25, 2021, which issued during the prosecution of European Patent Application No. 18826823.9.
IPR2021-01051 Institution decision dated Dec. 10, 2021.
Notice of Allowance dated Dec. 7, 2021, which issued during the prosecution of U.S. Appl. No. 17/394,807.
Notice of Allowance dated Dec. 6, 2021, which issued during the prosecution of U.S. Appl. No. 16/738,516.
Notice of Allowance dated Dec. 29, 2021, which issued during the prosecution of U.S. Appl. No. 17/210,183.
IPR2021-00383 Petitioners' Reply to Patent Owner's Response dated Jan. 5, 2022.
IPR2021-00383 Petitioners' Opposition to Patent Owner's Contingent Motion to Amend dated Jan. 5, 2022.
An Office Action dated Sep. 22, 2021, which issued during the prosecution of European Patent Application No. 20714289.4.
Summary of Examination Notice dated Jan. 6, 2022, which issued during the prosecution of Chinese Patent Application No. 201880064313.X.
An Office Action dated Jan. 12, 2022, which issued during the prosecution of U.S. Appl. No. 17/101,787.
Sündermann, Simon H., et al. “Feasibility of the Engager™ aortic transcatheter valve system using a flexible over-the-wire design.” European Journal of Cardio-Thoracic Surgery 42.4 (2012): e48-e52.
Serruys, P. W., Piazza, N., Cribier, A., Webb, J., Laborde, J. C., & de Jaegere, P. (Eds.). (2009). Transcatheter aortic valve implantation: tips and tricks to avoid failure. CRC Press.—Screenshots from Google Books downloaded from: https://books.google.co.il/books?id=FLzLBQAAQBAJ&1pg=PA198&ots=soqWrDH-y_&dq=%20%22Edward%20SAPIEN%22&lr&pg=PA20#v=onepage&q=%22Edwards%20SAPIEN%22&F=false ; Downloaded on Jun. 18, 2020.
Notice of Allowance dated May 7, 2020, which issued during the prosecution of U.S. Appl. No. 16/637,166.
An Office Action dated Aug. 7, 2020, which issued during the prosecution of U.S. Appl. No. 15/668,659.
Notice of Allowance dated Jul. 29, 2020, which issued during the prosecution of U.S. Appl. No. 16/132,937.
An Office Action summarized English translation and Search Report dated Jul. 3, 2020, which issued during the prosecution of Chinese Patent Application No. 201780061210.3.
Tchetche, D. and Nicolas M. Van Mieghem: “New-generation TAVI devices: description and specifications” EuroIntervention, 2014, No. 10:U90-U100.
An International Search Report and a Written Opinion both dated Jun. 24, 2020, which issued during the prosecution of Applicant's PCT/IL2019/051398.
Symetis S.A.: “Acurate neo™Aortic Bioprosthesis for Implantation using the Acurate neo™ TA Transapical Delivery System in Patients with Severe Aortic Stenosis,” Clinical Investigation Plan, Protocol No: 2015-01, Vs. No. 2, 2015:1-76.
Notice of Allowance dated Sep. 10, 2020, which issued during the prosecution of U.S. Appl. No. 15/600,190.
An Office Action dated Jul. 29, 2020, which issued during the prosecution of U.S. Appl. No. 16/269,328.
Notice of Allowance dated Aug. 26, 2020, which issued during the prosecution of U.S. Appl. No. 16/269,328.
An Office Action dated Jul. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/324,339.
Notice of Allowance dated Aug. 28, 2020, which issued during the prosecution of U.S. Appl. No. 16/324,339.
Office Action dated Jul. 27, 2022 from The U.S. Patent and Trademark Office in U.S. Appl. No. 16/881,350.
Patent Owner's Sur-reply to Petitioners' Reply to Preliminary Guidance, IPR2021-01051, U.S. Pat. No. 10,702,385, filed Aug. 23, 2022.
Petitioners' Reply to Preliminary Guidance, IPR2021-01051, U.S. Pat. No. 10,702,385, filed Aug. 2, 2022.
Related Publications (1)
Number Date Country
20200330227 A1 Oct 2020 US
Provisional Applications (5)
Number Date Country
61588892 Jan 2012 US
61555160 Nov 2011 US
61537276 Sep 2011 US
61525281 Aug 2011 US
61515372 Aug 2011 US
Continuations (3)
Number Date Country
Parent 16284331 Feb 2019 US
Child 16888210 US
Parent 15197069 Jun 2016 US
Child 16284331 US
Parent 14237258 US
Child 15197069 US
Continuation in Parts (1)
Number Date Country
Parent 13412814 Mar 2012 US
Child 14237258 US